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1. Prologue
Before we begin to define the current state 
of the art surrounding the field of silk-
based biomaterials for (bio)medical use 
and look toward their future, we feel it is 
important to spend some time considering 
the motivation of the research and the his-
tory of the material that has led us to today.
The issue of motivation for studies 
in the field of silk research is generally 
divided into bottom-up, curiosity-driven 
fundamental research and top-down, chal-
lenge-based activities.
Fundamental silk research hinges on 
the question, “what can we learn from 
nature?” This is clearly a wider topic than 
silk itself, but the overall approach helps 
frame scholarly activities in the area. We 
certainly have more to learn beyond under-
standing the silk fiber itself, and dozens of 
cross-disciplinary researchers worldwide are using both simula-
tion and experimentation[1] to make concerted efforts to under-
stand the evolution,[2] processing,[3] and performance of silk,[4] 
from the molecule[5] to the material.[6] However, as we broaden 
our interpretive horizons, we must remember that silks are bio-
logical materials, and thus are defined by their biology, before 
we attempt to transfer this knowledge to biomaterials, which 
are defined through their application.
2. Introduction
For the purpose of this progress review, we use the term silk 
to refer to protein-based fiber-forming materials spun by living 
organisms. We also include in our terminology silk-inspired 
proteins produced by recombinant approaches.
When studying silks, one must always appreciate that the 
results derived from testing any naturally obtained bio logical 
material are a product of both nature (its evolution) and 
nurture (its environment), with the latter typically constraining 
the property space of the former (although exceptions 
exist[4a,7]).
The biological definition of a silk is a structural protein that 
is spun into a fiber for use outside the body.[4a,8] In the wild, 
silks have undergone over 400 million years of “research and 
development” via natural selection, and after solutions to bio-
logical challenges that range from predation (spider webs) to 
housing (honey bees and wasps) and protection (silkworm 
cocoons).[4a,8] The ubiquity and widespread use of silk is a clear 
testament to its success, especially as it has arisen numerous 
times in independent convergent evolutionary events.[2c] Hence, 
Humans have long appreciated silk for its lustrous appeal and remarkable 
physical properties, yet as the mysteries of silk are unraveled, it becomes 
clear that this outstanding biopolymer is more than a high-tech fiber. This 
progress report provides a critical but detailed insight into the biomedical 
use of silk. This journey begins with a historical perspective of silk and its 
uses, including the long-standing desire to reverse engineer silk. Selected silk 
structure–function relationships are then examined to appreciate past and 
current silk challenges. From this, biocompatibility and biodegradation are 
reviewed with a specific focus of silk performance in humans. The current 
clinical uses of silk (e.g., sutures, surgical meshes, and fabrics) are dis-
cussed, as well as clinical trials (e.g., wound healing, tissue engineering) and 
emerging biomedical applications of silk across selected formats, such as silk 
solution, films, scaffolds, electrospun materials, hydrogels, and particles. The 
journey finishes with a look at the roadmap of next-generation recombinant 
silks, especially the development pipeline of this new industry for clinical use.
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looking at how silk materials have evolved can not only deter-
mine their performance in the present, but can also reveal 
common design criteria and molecular “blueprints” for high 
performance biological materials.[4a,9]
In unraveling the properties of silk, we have also begun to 
address common misconceptions regarding biological materials 
and their potential for industrial application. These are often 
tarred with a brush of sample variability, suggesting that they 
are unsuitable for engineering or medical applications where 
consistency is key. However, recent studies now show that the 
variation previously observed is typically a manifestation of a 
silk’s exquisite responsiveness to its surroundings (making 
silks incredibly “smart” materials).[4d,7a,10] Yet for uninitiated 
researchers, this can sometimes become unwanted variation if 
the they fail to ensure consistent sample preparation or testing 
environments. Hence, biological diversity and plasticity offer 
several important lessons for those wishing to make the best 
use of silk for their own applications.
At the other end of the spectrum is the widely held belief 
that biological materials automatically qualify as “biocompat-
ible” materials. While these materials, including many silks, 
are often biocompatible, simply labeling silk as “biocompatible” 
without context specific biocompatibility testing and critical 
assessment of the available evidence is not in the best interest 
of the field or, ultimately, patients. This mindset also perme-
ates into the assumption that all natural materials are “green” 
which without appropriate and carefully considered environ-
mental analysis, the use of the phrase ultimately detracts from 
any potential impact of these materials.
Once past our prejudices, at the interface of fundamental 
and challenge-based activities sits biomimetics. This specifi-
cally looks to nature to reveal concepts, processes, and systems 
that can be applied to solve human challenges.[11] While the 
term “biomimetics” was only coined by American biophysicist 
Otto Schmitt in the latter half of the 20th century,[11] humans 
have been looking to translate silk’s natural utility for their 
own use for millennia.[12] The simplest, most primitive forms 
of mimicry are examples of imitation of the spider’s use of 
silk to catch prey, as seen in the Australian Aborigines’ use of 
spider silk as fishing lines and New Guinean natives’ develop-
ment of fishing nets and bags.[13] However, the biological diver-
sity of silk soon inspired humans to adapt silk for their own 
needs (e.g., ref. [14]), extending the silk phenotype beyond its 
natural remit. Some of the first examples were the use of silks 
medicinally by ancient Greeks and Romans, who bundled up 
spider silk to treat wounds (Figure 1).[13] This was even noted 
by Shakespeare’s character, Nick Bottom, in A Midsummer 
Night’s Dream, who says, “I shall desire you of more acquaint-
ance, good Master Cobweb. If I cut my finger, I shall make bold 
of you.”[15]
However, the above examples describe the use of silk in its 
unprocessed, natural state. A step forward in the utilitarian 
evolution of silk came about with the realization that silk 
could be readily reprocessed into different forms. This was 
first performed at the macroscale by unwinding fibers from 
the nonwoven composite cocoons of the silkworm Bombyx 
mori to create textiles. This skill originated in China, and direct 
archeological evidence confirms human interactions with silk-
worm silk originating from the Neolithic period of the 4th mil-
lennium BC, with the discovery of examples of cut cocoons and 
rudimentary looms at numerous archeological sites.[16] Further 
archeological evidence suggests that the Indus Valley civiliza-
tion (in what is now Northern Pakistan) was also developing silk 
materials based on Antheraea silk. Therefore, sericulture—the 
act of rearing silkworms specifically for their silk—can be esti-
mated to have spread across South Asia from 5000–2000 BC.[17]
Textiles produced from silk were truly a disruptive product, 
as they required both a unique material and highly sophisti-
cated processing (programmable looms for weaving that were, in 
essence, the progenitor of modern computing).[18] As such, silk 
textiles were sufficiently valuable to become a formal currency 
for Chinese soldiers at the edges of the empire and were used to 
barter with the locals for goods.[16] Nevertheless, silk production 
remained a closely guarded secret within the Chinese empire 
for several thousand years, and when asked, traders would say 
it was “derived from the wool of sheep sprinkled with water and 
exposed to sunshine.” However, this product monopoly could not 
go unchallenged for long, and the establishment of trade routes 
(the “silk roads”), and the apocryphal industrial espionage that 
ensued, made silk technology available throughout the world. 
As a result, Bombyx mori silk has developed hand in hand with 
humans, through domestication and artificial selection of the 
moths for over 4000 years.[16] This extensive history is a testament 
to the success and suitability of this animal for large-scale indus-
trial agricultural development, as ≈980 billion animals are raised 
each year to produce ≈400 megatonnes of commercial silk.[19]
Adv. Healthcare Mater. 2018, 1800465
Figure 1. Timeline: Milestones in the emergence of silk for biomedical applications.
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Across millennia, silkworm has been a luxury item for the elite. 
However, Claudius Galenus of Pergamon (c. 131 to c. 211 AD) 
was the first to document a potential medical application of the 
silk thread. Galenus gained a reputation for treating gladiators 
whose tendons were severed in hand-to-hand combat and noted 
in his book De Methodo Medendi (150 AD) the use of several 
materials as sutures, including linen. He writes, “in many places 
under Roman rule you can obtain silk, especially in large cities 
where there are many wealthy women. If there is no such oppor-
tunity, choose from the material where you were living the least 
putrescible such as thin catgut.” Galenus’s teaching persisted 
for centuries after his death but was eventually lost.[20] The war 
surgeon Ambroise Paré (1510–1590) avoided cauterizing open 
wounds with boiling oil and reverted to using vascular ligatures 
made of silk or fine linen strips. However, only in 1869 did Joseph 
Lister introduce the first sterile silk suture into clinical practice.[20]
Throughout history, several alternative sources for textile 
silk beyond the domesticated silkworm have been sought, from 
the wild silkworms of India and Africa[21] to the more esoteric 
source represented by spider silk. The quest to commercialize 
spider silk, due to its favorable mechanical properties, seem-
ingly began with the inventions of Abbé Ramon de Termeyer in 
the 18th century for his reeling device.[22] Over the years, these 
inventions were followed by others, such as those of the civil 
war surgeon Burt G. Wilder.[23] The most successful attempts 
are probably those made by the Madagascan spider silk industry, 
which has produced, to date, only a handful of items destined 
for the elite.[24] Yet, while producing arguably mechanically 
superior materials compared to those made of silkworm silk, 
none of these endeavors were ultimately found to be scalable.
Hence, given the coveted nature of silk, the fact that indus-
trialists wished to replicate it may come as no surprise. In fact, 
nearly every single industrial fiber produced in the latter half 
of the 19th and throughout the 20th century, from rayon to 
nylon to Kevlar, has been developed in the hope that it would 
provide a suitable alternative to silk.[25] Nevertheless, even after 
150 years of concerted research and development, and although 
replication of the properties and performance of silkworm silk 
is now possible, similar success with spider silk, and specifi-
cally dragline silk, remains elusive. A complete overview of the 
history, progress, and trends in artificial silk spinning from a 
fiber performance perspective is available in a recent review 
that comprehensively covers this topic.[25]
Fortunately, the attempts to replicate various silks resulted 
in several distinctly important innovations that led the bioma-
terials field to consider silk as more than just a fiber.[12] Akin 
to the ancient Chinese realizing that a silkworm cocoon can 
be unspun, early attempts at creating artificial silk led to the 
conclusion that the silk fiber itself could be “unspun” back into 
a processable protein feedstock, which could then be solidified 
into a variety of forms. According to the original patents, this 
finding was largely motivated by a need to utilize the waste 
streams from the industry,[26] as the last tens to a hundred 
meters of silk from a cocoon could not be unraveled. (Today, 
this would be labelled an exercise in sustainability.)
To the best of our knowledge, the first attempt to create an 
artificial silk feedstock appeared at the turn of the 20th century, 
110 years ago. It began with the work of Baumann and Diesser, 
who proposed the dissolution of whole silk glands in formic 
acid.[27] In subsequent years, a notable race began between 
Japanese and German researchers in the 1920s, with patents 
granted in 1924–1927[26a,28] and 1928,[29] respectively, for the 
successful dissolution (and respinning) of artificial fibers using 
ZnCl2, Mg(NO3)2, and orthophosphoric acid as the main chao-
tropic agents. However, not until the 1930s did today’s familiar 
degumming using Na2CO3[30] and dissolution in LiBr appear.[26b] 
The latter report clearly noted the potential of silk regeneration/
reconstitution: “These solutions containing, if at all, only a small 
amount of salt, may be used in the known manner to produce 
artificial articles, such as fibers, films, or plastic masses.”
Beyond the replication of silk fibers for textile use, these feed-
stocks were originally intended for reprocessing into solid form 
to harness silk’s excellent insulating properties[26b] and enable 
the casting of films (to make fabrics water and air imperme-
able[31]). This was mainly because naturally derived materials 
were still superior in many aspects when compared to those 
arising from the burgeoning field of industrial polymers.[32]
Interestingly, nearly three decades passed before the first bio-
medical use for a regenerated silk was reported in the patent lit-
erature. In the 1960s, Bloch and Messores, of Ethicon Inc. (NJ, 
USA), were the first to propose the use of a LiSCN/LiBr recon-
stituted silk as a replacement for the standard wax coating used 
on silk sutures to reduce their limpness, fraying, and unwanted 
capillary action.[33] In the following years, while developments 
continued in the suture field, another two decades passed 
before the first examples of nonfibrous silk-based biomate-
rial patents were reported. In 1986, a silk fibroin:fibrinogen 
glue, based on the “standard” LiBr reconstitution approach, 
was developed by a Japanese firm.[34] This was followed by the 
first patent for a silk based porous scaffold in 1987, again from 
Japan, produced from a freeze-dried native silk solution (i.e., 
silk extracted directly from the silk gland).[35] The 1990s saw 
more patent applications from Japan, including powdered silk 
for wound dressings,[36] reconstituted silk films and molded 
gels for skin, blood vessel, and corneal coatings,[37] and colloidal 
silk for consumption in medicine.[38] However, in the 2000s, 
an explosion occurred in the USA in research and commer-
cialization activity around this area with the emergence of large 
patent families (>100) focused on the future medical exploita-
tion of these materials.[39]
In summary, looking back, the ability to unspin silk, and 
thereby reconstitute it, has been a monumentally disruptive 
development in the field. It represents a platform technology 
for the development of biomimetic structures that are built 
with silk but are not built to replicate silk. While gaps still 
undoubtedly exist in our knowledge surrounding the process of 
reconstitution and how this affects the integrity and application 
of the silk proteins undergoing it,[40] the unspinning process 
has been widely adopted throughout the biomaterials field. This 
is perhaps best evidenced by the impact of the landmark review 
of Altman et al.[41] 15 years ago and the more recent protocol of 
Rockwood et al.,[42] which leads us in the present day.
3. Silk: Hierarchical and Crystal Structures
The fundamental building blocks of the silk biopolymer are 
amino acids that, through their sequence specificity and 
Adv. Healthcare Mater. 2018, 1800465
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subsequent secondary, tertiary, and quaternary structures, 
govern the protein’s overall function. In nature, silk and silk-
like proteins are made by several organisms such as spiders, 
silkworms, scorpions, mussels, bees, and ants. However, the 
silk fibroins and silk-like proteins of each organism exhibit dif-
ferent physical and biological characters due to their different 
amino acid sequences, spinning conditions, and hierarchical 
structures.[7b,43] The hierarchical structures of silk proteins vary 
among silk types.[43a,44] Silk proteins produced by spiders and 
insects are referred to as silk spidroin and silk fibroin, respec-
tively. The term “silk fibroin” is commonly used to differentiate 
“virgin” silk (silk filament still encased by sericin) or silk cocoons 
(i.e., the sericin-coated silk thread arranged into a cocoon) from 
purified silk (i.e., degummed; see Section 6). For the purpose of 
this progress review, we will use the term silk fibroin to refer to 
degummed (Bombyx mori) silk unless otherwise stated.
As discussed in the previous section, the silk fibroin of the 
domesticated silkworm (Bombyx mori) is the most well studied 
silk for biomedical applications due to its established supply 
chain, abundance, and clinical track record. The Bombyx mori 
protein fiber is a composite material comprising a semi-crystal-
line silk core (i.e., silk fibroin), which is mainly responsible for 
the load-bearing capacity, and an outer layer of sericin, which 
functions as a gumming agent.[45] However, emerging evidence 
suggests that sericin also inhibits the premature conversion of 
soluble silk (silk I) into β-sheet-rich silk.[46]
The Bombyx mori silk protein (i.e., silk fibroin) is very large 
and can be subdivided into light (≈26 kDa) and heavy (≈391 kDa) 
chains that are linked by a single disulfide bond at the C-ter-
minus[47] (Figure 2). The C-terminal and N-terminal capping 
sequences are completely nonrepeating amino acid residues. 
The mechanical properties of silk fibroin arise due to the block 
copolymer-like arrangement of the silk heavy chain, which con-
tains 11 short hydrophilic regions typically 31 amino acid long 
and 12 hydrophobic blocks that account for 94% of the silk 
heavy chain. These hydrophobic blocks contain predominately 
glycine-X (GX) repeats, where X is alanine (A) (65%), serine (S) 
(23%), or tyrosine (Y) (9%).[47a] These GX blocks can be broadly 
classified into three groups: i) a highly repetitive GAGAGS 
sequence that contributes to the bulk of the crystalline regions 
Adv. Healthcare Mater. 2018, 1800465
Figure 2. Silk structure. A) Solution conformation of Bomyx mori silk. Hydrophobicity pattern of the heavy chain with possible chain folding and micelle 
assembly of silk fibroin in water. Adapted with permission.[50] Copyright 2003, Macmillan Publishers. B) 2D silk fibroin schematic. Adapted with permis-
sion.[51] Copyright 2018, American Chemical Society. C) Primary structure of the Bombyx mori silk heavy chain. R01 to R12 and A01 to A11 represent 
the arrangement of 12 repetitive and 11 amorphous regions, respectively. The approximate amino acid sequence of the R10 is shown by combination 
of sequences of i, ii, and iii. Adapted with permission.[52] Copyright 2005, American Chemical Society. D) Hierarchal structure of spider silk. Adapted 
with permission.[53] Copyright 2011, Elsevier. E) Primary structure of spider silks. Adapted with permission.[54] Copyright 2017, American Association 
for the Advancement of Science.
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and is typically found at the beginning of each motive, ii) a 
relative less repetitive sequence containing hydrophobic and/
or aromatic residues, namely, GAGAGY, GAGAGV, and GAGA-
GVGY, which form semi-crystalline regions, and iii) motifs 
similar to i) except for the presence of an AAS motif, which 
typically exists at the C-terminus of each motif and may play 
a role for sheet-breaking.[48] Bombyx mori silk fibroin lacks the 
tripeptide sequence arginine, glycine, and glutamic acid (RGD) 
that is typically exploited by cells to mediated cell–substrate 
attachment via integrin engagement; however, the N terminal 
of the silk heavy chain contains a fibroblast growth-promoting 
peptide.[49] Nevertheless, a sequence specificity exists between 
different silkworm silks; for example, the Indian non-mulberry 
tasar silkworm (Antheraea mylitta) contains RGD sequences 
that are absent in Bombyx mori silk.
Spider dragline silk, one of the toughest materials known to 
humankind, is composed of a skin layer and a bundle of micro-
fibrils (Figure 1).[5b,55] The microfibrils are composed of aligned 
granules, and their silk molecules form an amorphous phase 
and β-sheet-rich crystalline regions.[5b] In both spider and silk-
worm silk fibers, the aligned β-sheet structure provides cross-
links between the β-sheet domains embedded in an amorphous 
matrix that consists of less orderly structures in the form of 
random coils, helices, and β-turns.[56] These β-sheet crystals are 
critical structures in the hierarchical structures of silk fibers, 
because they play an essential role as cross-linking points and 
realize the stiffness, strength, toughness, and characteristic 
deformation behaviors.[56a,b,57]
The amino acid sequences that form the β-sheet are 7–9mer 
alanine sequences for Nephila clavipes dragline silk and 
GAGAGS for Bombyx mori,[58] whereas other silkworm silk spe-
cies use polyalanine sequences to form the β-sheet structure.[6a] 
The influence of the number of alanine residues on the sec-
ondary structure and assembly behaviors of silk molecules has 
been studied using wide angle X-ray crystallography as well as 
solid-state nuclear magnetic resonance (NMR) spectroscopy. 
Those data from X-ray and NMR analyses reveal that short 
poly(alanine) sequences, such as 6mers or shorter, form a 
packed rectangular arrangement, while poly(alanine) sequences 
longer than 7mers pack in a staggered arrangement.[59]
The β-sheet is the most fundamental secondary structure in 
silk-based (bio)materials. The predominant β-sheet structure 
plays a key role in stabilizing silk materials via physical cross-
links, as the β-sheet behaves as a cross-linking point. Crystal 
structures of silk β-sheets have been characterized using wide-
angle X-ray analysis. The crystal structure of Bombyx mori silk 
fiber has a unit cell with the space group P21-C22.[60] The crystal 
lattice of the Bombyx mori silk fiber reported by Marsh et al. 
had unit cell dimensions of a = 9.40 Å, b = 9.20 Å, and c (fiber 
axis) = 6.97 Å, while Takahashi et al. reported cell dimensions of 
a = 9.38 Å, b = 9.49 Å, and c (fiber axis) = 6.98 Å.[60] The lattice of 
other silks, such as Antheraea yamamai (Japanese silk moth), has 
been characterized and reported by many groups.[57b] The unit 
cells contain four molecular chains, a pair of which symmetrically 
forms a β-sheet structure via hydrogen bonds. The up-molecular 
and down-molecular chains also alternate with each other in an 
antiparallel manner. Each silk has a different crystal lattice, which 
can be attributed to differences of the silk amino acid sequences. 
However, the relationship between the crystal lattices of different 
silks and the subsequent characteristics of silk fibroin as a 
biomaterial remains largely unexplored, despite the fact that crys-
tallinity (i.e., the amount of crystalline region) affects the physical 
and biological properties of silk-based biomaterials.
4. Hydration State
Silk and regenerated silk fibroin materials are expected to 
exhibit high toughness and ductility because of the excel-
lent mechanical characters of spider (dragline) silks found in 
nature.[9,61] However, in addition to sequence specificity, the 
hydration state of silk is critical for its performance.[62] For 
example, most native spider silks show significant fiber con-
traction when transitioned from a dry state to a high humidity 
environment. Exposure to humidity facilitates the rearrange-
ment of the noncrystalline GPGXX sequence of orb web silks 
and the glycine-glycine-X 310 helices in nonorbicularian species 
(which lack the GPGXX sequence). This occurs due to disrup-
tion of hydrogen bonding by these sequences, which facilitates 
the transition from a parallel arrangement for the fiber axis to 
a lower energetic configuration that is accompanied by fiber 
shrinkage and thickening.[63] Thus, water is a key component 
that enables spiders to tailor the properties of their silks during 
spinning and for in situ web tightening (a phenomenon also 
known as “supercontraction”).[63]
In nature, silkworm cocoons and spider webs/draglines 
are tough structural materials that perform their function; for 
example, to capture prey in the spider’s web or to protect the devel-
oping moth from predators and infection.[57b] The mechanical 
robustness of the native silk fiber has been exploited by humans 
for biomedical applications both in preclinical (e.g., ref. [64]) 
and clinical trials (detailed below). For example, silk fibroin scaf-
folds proposed for bone repair have shown a high compressive 
strength of ≈13 MPa when reinforced with Bombyx mori silk 
fibers.[64] A similar approach has been taken to enhance the 
mechanical properties of Bombyx mori silk hydrogels for car-
tilage tissue engineering.[65] Recently, a high relative humidity 
of >97% was found to cause a dramatic increase in the tough-
ness and crystallinity of silk films.[6a] This finding exemplifies 
how an appropriate hydration of silk molecules and materials 
can achieve crystallization and plasticization simultaneously, 
resulting in a high-strength and tough silk material.
5. Silk for Tissue Engineering and Drug  
Delivery—Expectations, Hopes, and the Reality
An excellent delivery system for bioactive molecules (e.g., small 
molecular weight drugs, peptides, proteins, etc.) must meet 
a number of requirements that include, but are not limited 
to, biocompatibility, biodegradability, mechanical robustness 
and durability, and amenability to processing under ambient 
aqueous conditions that preserve the bioactivity of the payload. 
Many of these requirements also apply for tissue engineering 
applications aimed at delivering or recruiting (endogenous) 
cells, although these silk constructs must also be able to pro-
vide cells with the necessary physical and biological cues to 
achieve the desired function.
Adv. Healthcare Mater. 2018, 1800465
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5.1. Silk Biocompatibility
The exact set of biocompatibility requirements is application 
specific, although many preclinical studies simply cite that silk 
can meet all the necessary requirements, or they make refer-
ence to silk as a “clinically approved” biomaterial for use in 
humans. However, this ignores our appreciation that a uni-
versal biocompatibility does not exist: a material needs to be 
fit for its intended use[66] (as documented by dedicated bio-
compatibility studies); thus, its performance is context specific. 
The clinical approval of silk typically refers to its load bearing 
applications; degummed Bombyx mori silk fibers processed into 
a knitted surgical mesh (SERI Surgical Scaffold manufactured 
by Sofregen Inc., Medford, MA, USA), silk sutures (coated with 
waxes, Ethicon Inc. and several other manufacturers), and silk 
garments to treat dermatological conditions are in wide use 
today in the clinical setting. Therefore, their performance in 
humans is becoming better documented in the literature[41,67] 
and is accompanied by a cadre of clinicians with experience 
working with these silk materials.
Dedicated biocompatibility assessment is critical when gen-
erating novel silk formats (e.g., (nano)particles, hydrogels, scaf-
folds, films, coatings, etc.) to address areas of unmet clinical 
need or when applying existing silk technologies to new indica-
tions. Any nonautologous material will elicit an initial foreign 
body response that reflects the first steps of tissue repair.[68] 
Therefore, ensuring that the foreign body response is transient 
rather than chronic is a prerequisite to ensure that clinical end-
points can be met. Overall, biomaterial performance depends on 
the implantation site, size, geometry, surface topography, and 
physical characteristics.[68] A systematic literature review[69] exam-
ining the performance of silk constructs (e.g., vascular grafts, 
ligaments, and wound dressings for skin grafting) in small and 
large animal studies overwhelming showed that a variety of dif-
ferent Bombyx mori silk constructs performed well across the 
broad spectrum of indications and animal models.[69] Direct 
in vivo comparison of silk with commonly used natural (e.g., 
collagen) and synthetic (e.g., polycaprolactone, polylactic acid, 
poly[lactide-co-glycolic acid]) biomaterials indicates that Bombyx 
mori silk fibroin is typically at least as good as these synthetic 
materials and often superior than other natural biopolymers.[69]
As new applications for silk emerge, appropriate biocompati-
bility studies must be performed to support these developments. 
For example, silk nanoparticles for anticancer drug delivery are 
typically designed for intravenous administration[70] and thus 
require hemocompatibility assessments because biological 
performance cannot be deduced by extrapolating results from 
macroscopic films[71] to nanoscale particles.[72] An initial proof of 
biocompatibility is a first step to translate silk technologies from 
the bench to the clinical setting. For example, regulatory frame-
works imposed by the Pharmaceuticals and Medical Devices 
Agency Japan, the Food and Drug Administration (FDA, USA), 
the Medicines and Healthcare Products Regulatory Agency 
(UK), and the European Medicine Regulatory Agency (EU) for 
medical devices (e.g., Regulation (EU) 2017/745 to obtain CE 
marking analogous to the Class III Premarket Approval/510(k) 
in the USA, and the Australian Register of Therapeutic Goods 
certificate of inclusion) stipulate that a biological safety assess-
ment needs to be conducted first (by an ISO certified laboratory, 
in conjunction with a notified body) before progressing the 
device to first-in-man clinical assessment. Materials of animal 
or allogeneic origin need to fulfill additional safety require-
ments (e.g., absence of infectious agents such as retroviruses, 
etc.) before use in humans. However, from a regulatory per-
spective, Bombyx mori silk is regarded as a non-animal product 
(EU Council Directive 93/42/EEC, rule 17).
Reports on the biocompatibility of silk in humans come pri-
marily from silk sutures (reviewed in ref. [41]) that have been 
in use for several centuries[20] and from SERI Surgical Scaf-
fold that obtained 510(k) clearance by the FDA in 2008 and 
underwent a market launch in 2013. Histological evidence of 
69 breast tissue samples (by 60 patients) taken at stage 2 in 
patients undergoing two-stage breast reconstruction with SERI 
Surgical Scaffold showed a mild inflammatory response in 59 
patients, as confirmed by histology. This consisted of an infil-
tration of mostly macrophages and occasional multinucleated 
giant cells that phagocytosed the silk fibers, as well as occa-
sional lymphocytes and, rarely, neutrophils or polymorphonu-
clear cells.[73] Ordered collagen deposition was observed, with 
minimal or no encapsulation of the silk surgical mesh. These 
clinical trial data[73] were similar to observations made in a 
sheep study.[74] However, one patient had a postoperative hema-
toma that led to mesh removal.[73]
Synthetics are now the most widely used suture material, 
but silk sutures are still in demand for specialized applications 
where exquisite handling is of paramount importance (e.g., eye 
surgery). Silk sutures are strong, are easy to handle, lie flat on 
the tissue surface, and allow for secure knots. Adverse reactions 
to silk sutures are typically reported for virgin silk, where the 
silk filaments are still coated with sericin (and often with addi-
tional waxes or silicones).[41] There is an ongoing debate about 
the potential role of sericin in these adverse reactions. However, 
emerging evidence suggests that sericin on its own shows a low 
allergenic and immunogenic profile in mice; in fact, this pro-
file is similar to that seen for silk fibroin or alginate.[75] These 
observations are supported by in vitro data with macrophages: 
extracted sericin from Bombyx mori silk cocoons showed no 
significant release of the inflammatory marker TNF-α; sim-
ilar observations were made with silk fibroin.[76] However, 
extracted sericin in combination with bacterial lipopolysaccha-
ride induced TNF-α release (but not for the silk fibroin group). 
Furthermore, recoating of silk fibroin with sericin showed no 
macrophage response, while virgin silk induced a high level 
of TNF-α release.[76] These data suggest that other leachable 
compound(s), or these compounds combined with sericin, 
may be responsible for the adverse clinical reactions reported 
for silk.[69,76] For example, patients subjected to bilateral cata-
ract surgery showed no suture reaction on the first eye but a 
severe reaction on the second eye when it was treated six to 
three months later. This suggested that these patients had 
undergone a sensitization toward virgin silk. Prompt removal 
of the offending silk suture resulted in significant clinical 
improvement.[77] Examining the clinical literature regarding 
silk sutures and identifying the exact cause of the adverse reac-
tion are challenging because often little (or no) information is 
provided about the exact nature of the silk suture (e.g., virgin 
silk, type of coatings, etc.). Nonetheless, an allergic response to 
Bombyx mori virgin silk is documented for the occupational and 
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domestic setting (reviewed in ref. [78]). For example, exposure to 
virgin silk fibers and repurposed silk waste (e.g., silk floss incor-
porated into rugs and bedding) has been linked to the develop-
ment of asthma in silk weavers[79] and children,[80] mounted by 
an IgG and IgE immune response.[81] Textile workers have an 
increased risk of developing chronic obstructive pulmonary dis-
ease, and this risk is highest in silk workers.[82]
Complete and reproducible sericin removal from Bombyx 
mori silk (a.k.a. degumming) is an essential step in silk utiliza-
tion. Clinically acceptable limits for residual sericin levels for 
marketed silk products have not been released into the public 
domain (note that SERI Surgical Scaffold is described by the 
manufacturer as highly purified silk with ≥95% purity). Cur-
rent evidence from both preclinical in vivo studies and clinical 
experience in humans across a range of applications indicates 
that Bombyx mori silk fibroin is biocompatible, provided that all 
other contaminants are successfully removed.
Sericin has traditionally been linked to the adverse effects 
reported for virgin silk (reviewed in ref. [78]). However, over the 
past decade, sericin has emerged as an interesting biopolymer 
(reviewed in ref. [83]), and dedicated biocompatibility studies are 
now showing encouraging results in relation to the allergenic 
and immunogenic profile of sericin (e.g., ref. [75]). An increasing 
number of studies report the biomedical use of the biopolymer 
sericin. For example, the development of composite sericin/
silicone nerve guides[84] or sericin/polyacrylamide hydrogels pro-
posed for dermal repair.[85] Preliminary Phase I clinical trials using 
sericin composite wound dressings for split-thickness skin grafting 
are on going and the results are eagerly awaited (NCT01539980 
and NCT02643680 reported at www.ClinicalTrials.gov).
5.2. Silk Biodegradation
Silk sutures are classified by regulatory agencies as non-biode-
gradable because regulatory guidelines expect a loss of most 
tensile strength within 60 days postimplantation. Over this time 
scale, silk sutures do not lose their mechanical performance, 
as they require longer time frames to degrade in humans.[41] 
In patients undergoing two-stage breast reconstruction, histo-
logical evidence of breast tissue samples taken from 60 patients 
at stage 2 (median 152 days after initial scaffold implantation, 
range 74 to 357 days) showed consistent SERI Surgical Scaffold 
degradation (although this was not quantified). The one excep-
tion was a patient that had a postoperative hematoma, which 
was accompanied by an apparent lack of silk degradation.[73]
The silk protein is known to degrade in vitro and in vivo in 
response to proteolytic enzymes,[69] as exemplified by studies 
with silk films (e.g., ref. [86]) and porous silk scaffolds (e.g., 
ref. [87]). Experience with SERI Surgical Scaffold in a sheep 
model of two-stage breast reconstruction showed progressive 
degradation and vascularization of the silk mesh: at 1 month 
postimplantation, tissue ingrowth and marked vascularization 
were evident; at 4 months, the mesh was no longer felt through 
the skin; and at 12 months, the mesh degradation and vascu-
larization were scored as mild but with substantial silk loss that 
precluded mechanical testing of the remaining SERI Surgical 
Scaffold.[74] At 12 months, the SERI Surgical Scaffold had stim-
ulated extensive type I collagen deposition and the resulting 
tissue was mechanically strong.[74] Clinical hernia repair in a 
horse showed incomplete SERI Surgical Scaffold degradation at 
2 years postimplantation, but no hernia relapse.[88]
The time scale for silk degradation depends on a number of 
factors, including, but not limited to: i) the amount of material, ii) 
gross morphology, iii) silk secondary structure, iv) silk treatment 
history, v) mechanical environment, and vi) implantation site 
(or final destination). The implantation site directly impacts the 
type of proteolytic enzyme encountered by the silk, because these 
enzymes vary between tissues, cells, and subcellular location.
Silk fibroin sequence alignment indicates a susceptibility 
to a number of proteases (e.g., protease XIV, α-chymotrypsin, 
proteinase K, papain, matrix metalloproteinases, collagenase, 
etc.)[51,89]). Nonetheless, predicting silk fibroin degradation simply 
based on the primary sequence is unreliable; for example, chymo-
trypsin has 434 cleavage sites in the silk heavy chain and 81 in the 
light chain, while protease XIV has 348 in the heavy chain and 41 
in the light chain. Despite numerous cleavage sites, chymotrypsin 
treatment for 20 days had no quantifiable effect on silk fibroin, 
while protease XIV significantly degraded silk fibroin in vitro.[51] 
Papain, a cysteine protease enzyme that mimics the activity of 
lysosomal enzymes, has 26 cleavage sites in the silk heavy chain 
(albeit exclusively in the amorphous regions) and 15 in the light 
chain, and it caused significant silk fibroin degradation over 20 
days but at a slower rate than protease XIV. Similar observations 
were made with isolated lysosomal enzyme preparations.[51]
Overall, these studies exemplify that the structure beyond 
the primary sequence is of critical importance for silk degra-
dation. The current working model supports the notion that, 
for Bombyx mori silk, degradation begins with the 11 hydro-
philic amorphous segments in the silk heavy chain, as well as 
the C-terminal and N-terminal and the silk light chain, which 
consist of completely nonrepeating amino acid sequences; 
this is then followed by degradation of the more crystalline 
sequences.[51,61c,89] The tightly packed crystalline domains are 
degraded last.[90] Furthermore, the silk format is a critical factor 
in determining degradation rates, as in vivo studies in rodent 
models indicated faster degradation for open silk structures 
than for tightly packed monolithic silk fibroin films (rank order: 
hydrogel > silk scaffold > monolithic film).[69]
Protease XIV is a useful model enzyme for studying silk degra-
dation and for comparing with earlier studies. However, protease 
XIV is a nonmammalian enzyme cocktail, so it must not be used 
to deduce or predict biocompatibility performance. Silk, as a pro-
tein-based biopolymer, is commonly considered to yield harm-
less biodegradation products; however, a more critical inspec-
tion of silk and its degradation products is timely. For example, 
silk fibrils have molecular-level similarity to amyloid fibrils,[91] 
and they were also reported to enhance amyloidosis of amyloid 
protein through a mechanism based on cross-seeding effects.[92] 
However, when silk nanofibrils and microfibrils were composed 
of β-sheets, which are known to affect various properties of silk 
fibers, they demonstrated no significant cytotoxicity toward in 
vitro neuronal cells. When the silk fibroin was degraded with 
chymotrypsin to yield mainly unordered soluble fragments with 
a low β-strand content, the degradation products caused no sig-
nificant amyloidosis. By contrast, significant cytotoxicity was 
observed when silk fibroin was degraded with protease XIV due 
to the formation of soluble β-sheet rich fragments.[61c]
Adv. Healthcare Mater. 2018, 1800465
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Formation of β-amyloid structures is a concern because amy-
loid beta fibrils are a hallmark of Alzheimer’s disease.[61c,93] 
Preliminary studies in mice injected with self-assembling silk 
fibroin hydrogels into the caudate putamen (striatum) showed 
no decline in cognitive function or animal behavior over the 
6 week study period.[94]
6. Processing of Silk Cocoons—Generating  
Silk for Biomedical Use
Unspinning the Bombyx mori silk cocoon and degumming to 
remove sericin are two crucial steps that yield silk suitable for 
biomedical use. Sericin can be removed by enzymatic methods 
(i.e., digesting sericin but not silk) or chemical processing (e.g., 
alkaline treatment). The latter approach is widely used and typi-
cally involves boiling silk in sodium bicarbonate for 20–60 min.[42] 
Degumming times as short as 5 min are also sufficient to remove 
sericin while minimizing silk damage, which usually occurs due 
to cleavage of the disulfide bond between the silk heavy and lights 
chain and fragmentation of the amorphous silk sequences in the 
silk heavy chain, which results in polydispersed silk.[95]
The degummed silk fibers can be fully reverse engineered by 
dissolving them in a high concentration chaotropic agent (for 
example, 9.3 M lithium bromide) at 60 °C over several hours 
to dissemble the higher order silk structure. The resulting 
silk fibroin solution is then dialyzed extensively against water 
to yield an aqueous silk solution that is stable at room tem-
perature for weeks and at 4 °C for several months.[42] When 
compared to native silk feedstock, this reverse engineered silk 
fibroin solution has a reduced solution conformation[96] and 
changed rheological properties.[40d]
The reverse engineered aqueous silk fibroin solution is com-
monly used to generate novel silk formats; for example films, 
fibers, scaffolds, and (self-assembling) silk hydrogels, as well as 
(nano)particles and (nano)coatings, and these formats are often 
achieved using an all aqueous processing under ambient condi-
tions. These mild processing conditions are ideal for preserving 
the activity of biologics.
7. Present Routine Clinical Use of Silk
The silk surgical mesh SERI Surgical Scaffold, silk sutures, 
and silk clothing to treat dermatological conditions are the only 
available products in routine clinical use today. All these prod-
ucts are manufactured by unwinding Bombyx mori silk cocoons 
and working with the silk thread. The clinical performance of 
silk sutures, their adverse effects, and the developments and 
potential solutions to improve suture performance have been 
reviewed previously.[41]
The SERI Surgical Scaffold technology is based on work con-
ducted by David Kaplan and co-workers at Tufts University, Med-
ford, MA, USA.[67a,97] The resulting patent portfolio and proprie-
tary silk processing technologies formed the basis of the spin-out 
company, Serica Technologies Inc. (Medford, MA, USA). Serica 
Technologies Inc. was able to prove to the FDA that SERI Sur-
gical Scaffold was “substantially equivalent” to existing surgical 
meshes and thus received 510(k) clearance to market the device. 
Serica Technologies Inc. was subsequently acquired by Allergan 
Inc., and the SERI Surgical Scaffold became commercially avail-
able for soft tissue support and repair in 2013 and was since 
then acquired by Sofregen Medical Inc. (Medford, MA, USA).
The current SERI Surgical Scaffold indications are for 
abdominal wall reconstruction[98] and investigational plastic sur-
gery applications, including total body contouring, brachioplasty, 
abdominoplasty, mastopexy, and breast reconstruction (Table 1).
The clinical performance of SERI Surgical Scaffold has been 
reported in the literature, which includes open label clinical 
trials and case reports (Table 1). Many of these encouraging 
clinical studies have been sponsored by Allergan Inc. A few 
independent retrospective clinical reports of small patient 
cohorts are reporting side effects (e.g., poor scaffold integration, 
see Table 1, Figure 3), often requiring surgical removal of the 
mesh.[67b,105,106] Therefore, some clinicians are abandoning the 
use of SERI Surgical Scaffold in their clinical practices,[105] and 
caution has been raised by others.[108] In 2013, Allergan Inc. vol-
untary withdraw several SERI Surgical Scaffold batches due to 
concerns about product sterility. How this might have affected 
the reported adverse events is not known.
We are familiar with silk for the textile industry, although 
silk garments are also used clinically to treat dermatological 
conditions, especially atopic dermatitis[109] and acne vulgaris[110] 
(Table 2). Mechanical skin irritation by harsh, rough (e.g., wool), 
and short (e.g., cotton) textile fibers is thought to contribute to 
atopic dermatitis. Furthermore, the skin of atopic dermatitis 
patients is often colonized with Staphylococcus aureus and the 
extent of colonization correlates with the severity of the disease. 
Silk fibers are very long (up to 1500 m) and smooth, so they 
minimize mechanical irritation when knitted into clothing. 
This silk clothing has been chemically modified to achieve 
antibacterial properties with the aim of reducing Staphylococcus 
aureus colonization of the skin. Sericin-free silk has also been 
covalently functionalized with 3-trimethylsilylpropyl-dimeth-
yloctadecyl ammonium chloride (AEM 5700/5772; AEGIS), 
resulting in commercial products (e.g., DermaSilk) for the 
treatment of atopic dermatitis. These silk garments use highly 
purified silk to minimize the risk of contact dermatitis.[111]
The silk garments are also knitted in a specific fashion to 
improve transpiration of sweat through the fabric (unlike eve-
ryday silk, which can worsen atopic dermatitis by trapping 
moisture). A randomized double-blind study in 30 patients with 
atopic dermatitis on both arms received an AEM 5700/5772 
functionalized silk sleeve and a silk-only sleeve. Patients treated 
with the silk sleeve showed a rapid improvement within 2 weeks 
but remained similar until the end of the study. The contralat-
eral arm treated with the AEM 5700/5772 functionalized silk 
showed similar results at 2 weeks but reached a greater level of 
improvement over 4 weeks.[109d] Other clinical trials using AEM 
5700/5772 functionalized silk garments in small patient cohorts 
reported substantial improvements in skin conditions (Table 2). 
By contrast, a randomized, controlled, observer-blinded clinical 
trial in 300 children showed only a 3% reduction in skin infec-
tion compared to control and was therefore not regarded as 
providing a significant clinical benefit.[109e] Overall, these clin-
ical trials are difficult to conduct, and the use of different silk 
garments (DermaSilk and DreamSkin, see Table 2 for details) 
undermines the power of the study. Furthermore, the selection 
Adv. Healthcare Mater. 2018, 1800465
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of patients with only moderate eczema (typically not treated 
with these types of garments) and the often limited wearing of 
the garments are not in line with the clinical recommendations. 
Therefore, these difficulties might result in underestimation 
of treatment effects. Overall, improving these silk garments to 
maximize their clinical performance warrants more research.
8. Clinical Trials Using Silk
The renewed interest in silk for biomedical use over the past 
20 years has resulted in a number of clinical trials; however, 
historically, these data sets have been difficult to source. Since 
2007, the FDA has mandated that drug and device manufac-
turers register clinical trials (www.ClinicTrials.gov) (Table 3).
Silk-based biomaterials show particular promise for skin 
wound healing due to their hemostatic properties, low inflam-
matory potential, and permeability to oxygen and water, as 
well as their ability to function as a barrier to bacterial coloni-
zation (Table 3). Sidaiyi, a silk fibroin sponge attached to a sili-
cone membrane, is a first generation wound dressing currently 
approved by the China Food and Drug Administration for clinical 
use in that country.[113] The Sidaiyi platform was first compared 
to silk fibroin films for wound healing applications in preclinical 
animal models, followed by a randomized, single blinded Phase I 
clinical trial. Silk films were made by casting an aqueous Bombyx 
mori silk fibroin solution in a mold and treating it at 65 °C and 
90% relative humidity for 100 min. The resulting 64.9 µm films 
were water-resistant (albeit their ability to bind a small amount 
of water that acts as a plasticizer) and formed 
an effective barrier against bacterial infection 
in vitro. The films were found to be biocom-
patible for their intended use according to 
ISO 10 993 tests for the biological evaluation 
of medical devices. In a rabbit full-thickness 
wound healing model, healing was three days 
faster in wounds treated with silk films than 
in wounds treated with Suprathel, a poly-
urethane-based synthetic wound dressing, 
and seven days faster than in wounds treated 
with the Sidaiyi wound dressing or phos-
phate buffered saline (PBS) treated controls 
(Figure 4). Silk-film-treated wounds showed 
the development of an organized epidermis 
by day 14 post-treatment and showed a mature 
and organized collagen matrix, hair follicles, 
and blood vessels histologically by day 21.[113] 
These results were further verified in a por-
cine full-thickness wound healing model prior 
to initiation of a Phase I clinical trial that ran 
from August 2013 to September 2014. This 
clinical trial enrolled 71 patients (36 randomly 
assigned to a silk film group and 35 to a Sid-
aiyi group). The silk-based wound dressings 
were used to cover donor sites following sur-
gical harvesting of split-thickness skin grafts; 
healing was significantly faster in the silk film 
group than in the Sidaiyi wound dressing 
group and 100% of the wounds were healed by 
day 14 postinjury in the silk film group. One case of inflamma-
tory reaction to the silk film was noted but the exact etiology was 
not determined. No cases of wound exudation were observed, 
indicating that the silk films maintained a clean wound environ-
ment with suitable moisture levels. The films showed good adhe-
sion to the wound surface and no changes of the wound dressing 
were required. As the wound healed, the silk films spontaneously 
detached from the regenerated skin areas. The exact mechanism 
underlying the improved clinical performance observed for the 
silk film group over the Sidaiyi group is currently unknown.
However, this study demonstrated the ability to manufacture 
silk films under Good Manufacturing Practice requirements 
and their successful use as wound dressings for skin repair and 
regeneration.[113] The potential for relatively easy modification 
of silk films for additional functionality, such as the incorpo-
ration of pores or the introduction of bioactive molecules,[114] 
makes silk films particularly attractive as wound dressings.
Thin silk films have also been used in prospective human 
clinical trials to repair acute and chornic tympanic membrane 
perforations.[115] These silk patches (Tympasil, Daewoong-Bio, 
Seoul, South Korea) were generated using reverse engineered 
Bombyx mori silk fibroin. The process leading to stabilization 
of these silk patches has not been established, but physical 
cross-linking is most likely because the brittle patches were first 
wetted in PBS to plasticize them to facilitate their trimming to 
the required size and surgical placement.
The first clinical trial involved 52 patients with acute trau-
matic tympanic membrane perforation who were treated with 
either a silk film or a paper-based membrane.[115b] A number of 
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Figure 3. Examples of SERI Surgical Scaffold implant loss in humans. A) Silk fibroin surgical 
mesh prior to implantation. B) Intraoperative view showing a free lying scaffold in the breast 
pocket. C) Retrieved scaffold surrounded with seroma. D) Interaoperative view of surgically 
removed scaffold with interpenetrated granulation tissue/scar plate (at > 5 months), and 
E) histology of retrieved sample showing granulation tissue with neutrophiles and giant cells 
at the material (1) interface (dotted line). (B,C) Reproduced with permission.[67b] Copyright 
2018, Elsevier. (D,E) Reproduced with permission.[106] Copyright 2015, Elsevier.
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conservative treatment modalities had been explored to support 
the (often spontaneous) healing of an acutely perforated tym-
panic membrane, including the placement of a “patch” on top 
of the damaged tympanic membrane. In this trial, the silk or 
paper patches were surgically placed and removed 7 days later, 
when the tympanic membrane appeared fully regenerated. The 
closure rate was similar for both the silk film and paper mem-
brane (92.3 and 84.6%, respectively), but the silk patch signifi-
cantly shortened the healing time from 16.7 to 13.7 days.
A similar improved healing with a silk patch was also pre-
viously reported in animal studies.[116] A follow-up study of 40 
patients with chronic traumatic tympanic membrane perfora-
tion showed that patients treated with a silk patch (Tympasil) 
had lower otorrhea, minor complication rates, and high patient 
satisfaction when compared with conventional perichon-
drium myringoplasty.[115a] The silk and autologous patches 
were removed one week after placement, and the postoperative 
hearing outcomes were not significantly different between the 
two treatment groups. However, the surgical time for the silk 
patch was very short (13.7 vs 29.5 min) and no sourcing of con-
nective tissue was required for the graft.[115a]
9. Preclinical Use of Silk—The Future
As we move from the routine clinical use of silk fibers to human 
clinical trials, the line between a silk thread-based medical device 
and other forms of silk starts to blur. A very wide spectrum of silk 
materials and formats is now emerging in preclinical studies.[167] 
We will first review silk solutions derived from reverse engineered 
Bombyx mori silk, followed by more complex formulations.
9.1. Silk Solution
Bombyx mori silk in its solubilized aqueous form has been 
investigated for a range of therapeutic applications, including 
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Table 2. Published data reporting the clinical use of silk garments for the treatment of atopic dermatitis in humans.
Year Article type Patient 
number





46 ND Children 4 months to 10 years. DermaSilk 
treatment or cotton clothing, topical moistur-
izing cream or emulsion
1 week Local score of treated and untreated 
area of same child (SCORAD index)
Overall DermaSilk decreased atopic 
dermatitis severity and local improve-




15 ND Children 0.6–9.2 years, body suits made out 
of DermaSilk and cotton (50:50). Cotton side 
also received topical corticosteroid
3 weeks Significant improvement of atopic 
dermatitis by assessing eczema area 
and severity (EASI index) irrespec-
tive of intervention. No significant 






22 ND Children 5 to 12 years old. DermaSilk, silk 
fabric, and cotton. Control on contralateral arm 
(silk for first for 2 weeks followed by cotton 
for rest of study period), topical moisturizing 
cream or emulsion, antihistamines prn
3 months DermaSilk arm significantly improved 
over study period when compared to 
cotton. Silk control treatment showed 





30 ND Age 3 to 31 years (mean 14.2). DermaSilk 
sleeve versus equivalent silk only fabric
1 month Significant decrease in SCORAD index 
for both groups. Silk only fabric rapid 
reduction over 2 weeks only while 
DermaSilk over 4 weeks; decrease in 
pruritus values similar during first 2 
weeks but further decrease for Der-
maSilk group until end of study
[109d]
2013 Retrospective, single 
center, double blind ran-
domized controlled trial
22 ND Age 4 to 18 months. Acute phases treated as 
per international guidelines. DermaSilk body 
and tights, or wear clothes in pure cotton; 
expect May to September
24 months Significant reduction in topical 
steroid use for DermaSilk group; 







300 University of Not-
tingham, National 
Institute for Health 
Research Clinical 
Research Network
Children aged 1 to 15 years. Standard care 
or standard care plus silk garment (either 
DermaSilk or DreamSkin). Eczema outcome 
and skin infections
24 weeks No statistical difference between 
groups for eczema area and severity 
(EASI index). Less frequent skin infec-
tions in silk group. Data not stratified 
for different silk garments. Included 
cost-benefit analysis rejects garments
[109e]
SCORAD: An atopic dermatitis scoring system combining extent, severity, and subjective symptoms. EASI: Eczema area and severity index. DermaSilk: AL.PRE.TEC. S.r.l. 
Italy, Silk is covalently functionalized with the antimicrobial 3-trimethylsilylpropyl-dimethyloctadecyl ammonium chloride (AEM 5700/5772; AEGIS). DreamSkin: DreamSkin 
Health Ltd UK. The silk fabric contains zinc-based antimicrobial and is coated with 2-(methacryloyloxy)ethyl-2-(trimethylammonio) ethylphosphate-stearylmethacrylate 
copolymer to from multilayer lamellar structures. The amphiphilic copolymer is proposed to serve as both a barrier and moisturizer.
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Table 3. Reported human clinical trials using silk.




Study results Primary outcome measure Identifier
SeriACL device trial for anterior 
cruciate ligament (ACL)  
reconstruction
Unknown. Status 
was active not 
recruiting
30 October 2008 Not posted Safety—measured by device related 
serious adverse events (time frame: 
12 months)
NCT00490594
Coated VICRYL Plus suture compared 
to Chinese silk in scheduled breast 
cancer surgery
Completed 101 May 2009 Posted Mean score on cosmetic outcome visual 
analog scale (time frame: 30 days (+/−5) 
postoperative)
NCT00768222
Clinical and economic outcomes 
with the use of SERI Surgical 





ND August 2014 Not posted Incidence rate of implant loss (SERI 
Surgical Scaffold and breast implant) 
(time frame: 52 weeks)
NCT02033590
Evaluation of HQ Matrix medical 
wound dressing for healing of donor 
site wounds
Completed 71 September 2014 Posted Time to wound healing (time frame: Days 
0, 3 ± 1, 7 ± 1, 10 ± 2, 14 ± 3, and 21 ± 3 
postoperation)
NCT01993030
SERI Surgical Scaffold use in 
reconstruction postmarket study for 
tissue support and repair in breast 
reconstruction surgery in Europe
Completed 100 February 2015 Posted Investigator satisfaction following use of 
SERI Surgical Scaffold evaluated using an 
11-point scale questionnaire (time frame: 
six months)
NCT01389232
Efficacy and safety of silk fibroin with 
bioactive coating layer dressing
Completed 29 May 2015 Not posted Clinical efficacy of wound dressing con-
taining silk fibroin with a sericin bioactive 
coating layer dressing in the treatment of 
split-thickness skin graft donor sites (time 
frame: within 14 days)
NCT02091076
SERI Surgical Scaffold postmarket study 
of soft tissue support and repair in 
breast reconstruction
Completed 17 March 2016 Not posted Incidence of Implant Loss (time frame: 
24 months postoperatively)
NCT01914653
A SERI Surgical Scaffold postmarket 
study of soft tissue support in ventral 
hernia repair
Completed 1 June 2016 Not posted Rate of hernia recurrence NCT01981044
Circumferential periareolar mastopexy 
using SERI Surgical Scaffold
Completed 14 June 2016 Not posted Size of the areola at 12 months 
as measured by physical mammometry
NCT02293798
Suture materials: an evaluation Completed 36 November 2016 Not posted Accumulation of soft deposits 
(time frame: 7 to 14 days)
NCT03410433
SERI Surgical Scaffold Support of the 
lower pole of the breast (SeriSupport)
Completed 76 November 2016 Posted Nipple to fold measurement on stretch 
(time frame: 1 year post op)
NCT02016612
Evaluation of HQ Matrix soft tissue mesh 
for the treatment of inguinal hernia
Unknown 144 December 2016 Not posted Postoperative recurrent rate 
(time frame: day 1 postoperation)
NCT02487628
The comparison of microbial adher-
ence to various sutures in patients 
undergoing oral surgery
Unknown. Status 
was not yet recruiting
30 May 2017 Not posted Bacterial counts on blood agar plates 
from each suture will be quantified in CFU 
(colony-forming units) and expressed as 
total bacteria/suture (time frame: outcome 
measure will be assessed 10 days after 
sample incubation for the different sutures 
obtained from each study participate)
NCT02653924




12 m postexplant 
safety f/u as agreed 
with UK MHRA)
4 July 2017 Not posted Safety (time frame: 12 months) NCT02205645
DACCa) in the REduction of Surgical 
Site INfection (DRESSINg)
Recruiting 712 December 2018 Not posted 30 day infection rate (time frame: 30 days) NCT02992951
Porous tissue regenerative silk scaffold 
for human meniscal cartilage repair 
(REKREATE)
Not yet recruiting 120 January 2021 Not posted Performance analysis of meniscal scaffold 
(time frame: At 12 months follow up)
NCT02732873
a)Although not silk fibroin, dialkylcarbamoylchloride (DACC) is found as a hydrophobic coating on spider webs.
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treatment of diabetes,[117] chronic wounds,[118] and inflamma-
tion.[119] Recent studies have investigated the utility of regen-
erated silk fibroin solution in preclinical animal models for 
the treatment of ocular conditions, including dry eye[120] and 
corneal injuries.[5b] Blindness from corneal disease affects over 
50 million people worldwide, while another 337 million people 
suffer from dry eye disease, representing a significant health-
care burden.[5b,121]
For example, silk fibroin treatment resulted in increased tear 
production and reduced the corneal irregularities observed in 
the absence of treatment in a mouse dry eye model (consisting 
of NOD.B10.H2b mice exposed to desiccation stress and scopol-
amine hydrobromide treatment for 10 days). Silk fibroin treat-
ment inhibited detachment of corneal epithelial cells, increased 
the number of conjunctival goblet cells, and inhibited the secre-
tion of inflammatory factors in the lacrimal gland of the eye, 
resulting in recovery of the tear film and mucus layer of the eye, 
improved corneal health, and reduced dry eye symptoms. Other 
anti-inflammatory agents, such as cyclosporine and corticoster-
oids, are available on the market for the treatment of dry eye, 
but silk has demonstrated a potential multitarget therapeutic 
effect that lacks the common side effects, such as pain and 
irritation, and other complications associated with long-term 
corticosteroid use.[44] Silk fibroin was demonstrated to stabilize 
the tear film through anti-inflammatory effects in the lacrimal 
gland and increased number of conjunctival goblet cells, but the 
mechanisms underpinning these observations are unknown.
Clinical approaches to treat corneal injuries are relatively 
limited and predominantly involve topical application of anti-
inflammatory or antimicrobial agents that do not promote 
tissue regeneration. A rabbit corneal injury model, which 
involved removal of a 7 mm diameter section of the central cor-
neal epithelium, was used to study the effects of an aqueous 
Bombyx mori silk fibroin solution (deemed “silk-derived pro-
tein” due to an additional autoclaving step during solubilization 
in lithium bromide that results in a heterogeneous population 
of low molecular weight silk fragments) on corneal epithe-
lial healing.[5b] All treatments showed corneal wound closure 
by 48 h postinjury, as indicated by fluorescein staining; how-
ever, treatment with silk accelerated the rate of wound healing 
threefold in the first 6 h postinjury. Relative to a PBS-treated 
control, silk treatment resulted in a significant increase in the 
numbers of proliferating Ki-67 positive epithelial cells, a dose 
dependent increase in epithelial cell attachment to the under-
lying basement membrane (as indicated by focal adhesion 
kinase staining), and a dose-dependent reduction in MMP-9, 
a metalloprotease involved in matrix remodeling and corneal 
repair. Finally, compared to the PBS-treated control, the silk-
treated group showed the formation of epithelial layers with 
tight junctions (ZO-1 staining) that more closely resembled 
those of healthy corneas.[5b] The potential of the silk solution 
in aiding wound healing is clearly demonstrated, but the exact 
mechanism of action is yet to be determined.
9.2. Silk Films
Silk films are among the most extensively explored biomaterials 
due to the ease of their fabrication and characterization and 
their versatility. Silk films have been explored for their potential 
in drug delivery.[61b] wound healing,[113,114,122] corneal replace-
ment, and flexible electrode[123] applications, among others.
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Figure 4. Silk fibroin films for wound healing applications. A) Healing 
of rabbit full-thickness wounds over a 21-day period following appli-
cation of Bombyx mori silk fibroin films, a polyurethane based wound 
dressing Suprathel, a silk-silicone wound dressing Sidaiyi, and a blank 
control treated with PBS. Silk-film-treated wounds healed 3 days faster 
than Suprathel-treated wounds and 7 days faster than Sidaiyi-treated and 
untreated wounds. B) Histological evaluation of the wounds: A moderate 
to complete epidermal organization in silk film treated wounds by day 14 
and mature regenerated tissue with well-formed collagen matrix by day 
21. C) Photographs of representative silk-film-treated partial thickness 
wounds in a human Phase I clinical trial, showing complete healing at day 
11, with an average time for complete wound healing of 9.86 ± 1.97 days 
(n = 36). D) Kaplan–Meier curves comparing cumulative healing by treat-
ment group. Reproduced with permission.[113] Copyright 2017, Wiley-VCH.
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Due to their transparent nature, silk films 
have been particularly well explored for 
ocular applications, including corneal and 
retinal regeneration. Silk films cast from 
the Indian non-mulberry tasar silkworm 
Antheraea mylitta (which as mentioned pre-
viously, unlike Bombyx mori silk, contains a 
natural RGD sequence) displayed a transpar-
ency (94.4 ± 0.006%) and a refractive index 
(1.44 ± 0.03) suitable for corneal repair.[124] 
These films supported the sprouting, 
migration, attachment, and proliferation of 
epithelial cells and keratocytes from rat cor-
neal explants to form complete cell sheets. 
Further, the films supported the growth of 
corneal limbal stem cells from the explants. 
Silk films cast from Bombyx mori silk have 
also been shown to support the adhesion and 
growth of human corneal epithelial cells as 
confluent epithelial sheets similar to those on 
the amniotic membranes used clinically.[125] 
Further, silk film topography[126] and biofunc-
tionalization[127] can be optimized to enhance 
corneal epithelial cell interactions.
Following implantation into the cor-
neal pockets of rabbits, acellular silk films 
made from Antheraea mylitta silk remained 
transparent and showed no signs of neo-
vascularization.[124] The films remained 
intact for at least two months and had no 
adverse effect on tear production, intraocular 
pressure, electrophysiology of the eye, or the 
histology or ultrastructure of the cornea. Silk 
film degradation can be controlled through 
modification of its β-sheet content and this 
has been extensively used to optimize silk 
biomaterial properties, including those of 
silk films for corneal applications.[59,128]
Silk films are also extensively explored 
for engineering corneal stroma[12,129] and 
the development of in vitro corneal models 
incorporating epithelium, stroma, and 
innervation.[129b] In addition to corneal repair 
and regeneration, silk films are also being 
investigated as a substrate for the develop-
ment of retinal prostheses. Recently reported 
retinal prostheses consisting of semiconductive poly(3-hexylth-
iophene) and conductive poly(3,4-ethylene-dioxythiophene)-
poly(styrenesulfonate) layers spin-coated onto silk films were 
shown to restore light sensitivity and visual acuity of the pri-
mary visual cortex in a well-established rat model of retinitis 
pigmentosa.[130]
Another promising application of silk films involves 
the introduction of various topographical features, such as 
microneedles. Microneedles are a minimally invasive and pain-
less alternative to hypodermic needles for drug administra-
tion. Silk microneedles have been made using micromolding 
approaches and a variety of masters, including those made by 
thermal drawing,[131] micromilling followed by wet etching,[132] 
and laser micromachining.[40a] DeMuth et al. proposed an 
interesting approach to develop implantable-tip composite 
microneedles using poly(acrylic acid) (PAA) and Bombyx mori 
silk fibroin for sustained vaccine delivery (Figure 5).[40a] Recent 
studies have shown the importance of antigen and adjuvant 
delivery kinetics in developing an optimal immune response, 
and persistent antigenic and inflammatory signals have been 
shown to elicit stronger responses when compared with tran-
sient bolus vaccine exposure.[97,133]
Silk has the advantage of controlled cargo release over time 
and can protect temperature-sensitive cargoes at elevated tem-
peratures, potentially allowing elimination of the “cold chain” 
that limits the availability of vaccines in developing countries.[134] 
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Figure 5. Implantable poly(acrylic acid)-silk fibroin microneedles for controllable vaccine 
release kinetics and enhanced immunogenicity. A) Schematic representation of the com-
posite microneedle fabrication process, showing fabrication of the silk fibroin tips followed 
by poly(acrylic acid) (PAA) pedestals. B) Photograph of the composite microneedles. C) Con-
focal microscopy images of composite microneedles loaded with fluorescently labeled model 
proteins in the silk tip (blue) or PAA pedestals (red) and D) delivery of fluorescently labeled 
model proteins to murine skin showing burst release and fast clearing from the PAA ped-
estal and slow, sustained release from the silk tip over 4 days (non-methanol-treated silk) or 
16 days (methanol-treated silk). i.d. inj refers to the intradermal injection control. Adapted with 
permission.[40a] Copyright 2014, Wiley-VCH.
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The composite microneedle consists of a silk fibroin tip loaded 
with the vaccine of interest and vaccine-loaded PAA microneedle 
pedestals.[40a] Upon exposure to the aqueous environment of the 
skin, the PAA rapidly dissolves within hours, releasing a bolus 
vaccine injection, while the silk fibroin tips remain implanted 
in the skin, releasing the vaccine over days. The microneedles 
were demonstrated to easily penetrate murine skin, with inser-
tion occurring several hundred micrometers below the skin 
surface. The skin healed within a day of patch application. A 
fluorescently labeled model protein was used to demonstrate 
vaccine release, and rapid PAA-delivered cargo clearance was 
observed from the treatment site within 24 h, followed by a slow 
release of silk-encapsulated cargo at the treatment site between 
4 days (when silk fibroin was not treated with methanol) and 
>16 days (when silk fibroin was treated with methanol), indi-
cating the ability to tune the drug release. When used to deliver 
a model whole-protein vaccine, the composite platform resulted 
in over a tenfold increase in antigen-specific T-cell and humoral 
immune responses when compared to traditional immuniza-
tion approaches. Notably, the microneedles were stored at room 
temperature for two months prior to testing, demonstrating the 
potential of this technology to eliminate the cold chain.
9.3. Silk Scaffolds
3D porous silk scaffolds can be manufactured via a number 
of approaches,[42] including the use of sodium chloride as a 
porogen leached from aqueous or organic silk solutions or fol-
lowing freezing and lyophilization of aqueous silk solutions.[40c] 
Early applications of these biomaterials predominantly focused 
on bone replacement and regeneration[135] due to the high 
mechanical strength of silk scaffolds and the potential for 
further reinforcement using degummed silk fibers, which 
approached the mechanical properties required for load-bearing 
bones.[64] Silk scaffolds have since found applications in a range 
of tissue engineering procedures for replacement and regenera-
tion of tissues,[129b,40c] as well as in the development of 3D in 
vitro tissue models.[129b,40c]
Recently, silk-based (Bombyx mori) fracture fixation devices 
have been developed using an approach that differs from 
the use of traditional highly porous silk scaffolds. Metal alloys 
are the current gold standard for fracture-fixation devices, 
despite issues arising from the extreme mechanical mismatch 
with native bone, which can have profound effects on wound 
healing and long term viability of the devices, particularly in 
pediatric patients.[137] Resorbable fixation devices, such as those 
made of poly(lactic-co-glycolic acid) (PLGA), poly(glycolic acid) 
(PGA), and, recently, silk, have the potential to address the dis-
advantages of metallic fixation devices. Silk, in particular, has 
the advantage of maintaining high strength while eliciting a 
low inflammatory response. Furthermore, silk degradation does 
not generate an acidic microclimate, as is typically observed for 
solid PLGA and PGA devices.[138] Bombyx mori silk fibroin fixa-
tion devices, including bone plates and bone screws, were man-
ufactured from lyophilized regenerated silk fibroin by casting 
in hexafluoroisopropanol, followed by machining into desired 
shapes (Figure 6).[139] Silk screws were successfully inserted 
into the hind limbs of rats (a nonfunctional preclinical model) 
to demonstrate the feasibility of the manufacturing and inser-
tion process. The rats were mobile immediately following sur-
gery and showed no visible signs of pain. The screws were well 
tolerated for up to 8 weeks, with early signs of resorption and 
formation of new bone evident around the threads of the screw. 
These devices are particularly appealing due to the potential 
for malleability when hydrated, which will allow shaping of 
the fixation plates for unique anatomical locations during sur-
gery, as well as providing the potential to incorporate BMP-2 
or antibiotics directly into the fixation devices to increase their 
functionality.
9.4. Electrospun Silk Biomaterials
Electrospinning has emerged as a popular technique for the 
development of biomaterials due to the extracellular matrix 
(ECM)-like fibrous nature of the nonwoven matrices and the 
control over fiber properties that can be achieved by tuning the 
electrospinning para meters. Electrospun silk fibroin has been 
explored for a range of applications, including wound dress-
ings,[114,140] bone[141] and ligament[142] replacements, and vas-
cular grafts.[143] Small diameter electrospun silk conduits have 
the potential to address the unmet need for off-the-shelf small 
diameter grafts with mechanical properties that match those of 
native vessels and support appropriate endothelial and blood 
cell interactions. In a comprehensive in vivo study of small 
diameter electrospun silk graft performance, Filipe et al. have 
demonstrated the production and performance of electrospun 
acellular silk fibroin grafts generated under aqueous conditions 
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Figure 6. Silk-based devices for fracture fixation. A) scanning electron 
microscopy image of a silk fibroin screw. Scale bar is 1 mm. B) Silk fibroin 
screw inserted into a rat femur at 4 weeks postsurgery. C,D) Cross-sec-
tions of the silk fibroin screw inserted into a rat femur at 4 weeks post-
surgery; sections stained with H&E and Masson’s trichrome, respectively. 
Adapted with permission.[139] Copyright 2014, Macmillan Publishers.
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in the absence of chemical cross-linkers (Figure 7).[143c] The 
electrospun silk fibroin grafts were significantly more elastic 
when compared with the gold-standard synthetic polytetra-
fluoroethylene (ePTFE) grafts (4.2 ± 0.5 MPa vs 31.9 ± 1.3 MPa) 
and more closely matched the elasticity of native rat vessels 
(2.1 ± 1.0 MPa), while demonstrating adequate burst pressure 
(849 mmHg) and suture pull-out strength (0.86 N). In vitro, the 
electrospun silk fibroin demonstrated excellent endothelial cell 
interactions and blood compatibility.
These characteristics are critical for the successful develop-
ment of next-generation vascular grafts, because only grafts that 
have both outstanding hemocompatibility and support endothe-
lialization will yield long-term performance. In an in vivo rat 
model of abdominal aortic replacement, electrospun silk fibroin 
scaffolds demonstrated excellent surgical handling and patency 
for up to six months and outperformed the gold-standard 
ePTFE grafts. Silk fibroin grafts supported rapid endotheliali-
zation, with endothelial cells present as early as 3 weeks post-
implantation and an almost complete monolayer forming by 
6 weeks (Figure 7). By contrast, the ePTFE grafts remained 
largely uncovered by endothelial cells even at 24 weeks postim-
plantation. The silk fibroin grafts showed intimal hyperplasia 
stabilization by 6 weeks, with smooth muscle cells (SMCs) 
showing a phenotypic switch to the less proliferative SMC-α 
expressing cells and increases in collagen, 
elastin, and proteoglycan production.[143c] 
This study demonstrates the potential for the 
use of silk fibroin in small diameter vascular 
graft applications and the findings warrant 
further preclinical testing in large animal 
models.
9.5. Hydrogels
Silk fibroin hydrogels have emerged as 
promising platforms for the delivery of 
small molecular weight drugs, biologics, 
and cells (reviewed in ref. [144]), as well as 
for mimicking of the ECM in 3D in vitro 
tissue models (reviewed in ref. [145]) and 
in vivo tissue fillers.[146] A classification 
of physically and chemically cross-linked 
Bombyx mori silk hydrogel is useful. The 
chemically cross-linked forms will not be dis-
cussed here (reviewed in ref. [144b]), because 
these systems do not capitalize on the facile 
self-assembly process of silk fibroin, a fea-
ture that sets it apart from many other (bio)
polymer-based hydrogels. This ability to self-
assemble arises because silk I can undergo a 
transition to silk II, which is rich in β-sheets, 
by the exclusion of solvating water molecules 
from the hydrophobic domains of the silk 
block copolymer. The GY sequences are key 
drivers for the formation of β-sheets, while 
the exact molecular abundance and compo-
sition allows fine tuning of the solution–gel 
transition process. Furthermore, pH respon-
sive elements within the silk structure allow silk to adopt a 
more ordered state (reviewed in ref. [147]).
Many different triggers have been used to control the solu-
tion–gel transition, including but not limited to i) vortexing, ii) 
ultrasound, iii) temperature, iv) osmotic stress, v) pH, vi) CO2 
acidification, vii) nonsolvent induced phase separation, and viii) 
direct electric current (reviewed in ref. [148]). Self-assembling 
silk fibroin hydrogels show shear thinning, making them ideal 
for injection and minimally invasive procedures. Treatment 
protocols are now available that yield self-assembling hydro-
gels in the absence of organic solvents, chemical cross-linkers, 
or UV irradiation. However, a potential disadvantage of self-
assembling silk fibroin hydrogels is that physically cross-linked 
systems (i.e., those with high β-sheet content) are opaque, due 
to the formation of nanocrystallites, and they are brittle, as they 
cannot undergo long range displacements, resulting in low 
elastic behavior and plastic deformation at strains >10%.
Electric fields yield silk fibroin hydrogels (also known as 
e-gels) that differ from most other physically cross-linked 
types.[149] First, the secondary silk structure of e-gels is domi-
nated by helical conformations, whereas other (pH-induced) 
hydrogels are rich in β-sheets. Second, e-gel formation is 
reversible: a switch in the DC current induces a migration of 
silk to the new positive electrode (this is possible because of 
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Figure 7. Electrospun silk fibroin biomaterials for vascular applications. A) Electrospun silk 
fibroin graft morphology. Scale bar is 10 µm. B) Electrospun silk fibroin grafts implanted in a 
rat model of abdominal aortic replacement: at the time of implantation (left), 6 weeks (middle), 
and 24 weeks (right) postimplantation. C) Endothelialization of implanted silk fibroin grafts 
as demonstrated by vWF+ staining (red) at 6 weeks postimplantation in distal (left), middle 
(middle), and proximal (right) regions. D,E) In vitro assessment of blood compatibility of 
electrospun silk fibroin biomaterials, compared to ePTFE, as indicated by formation of a fluo-
rescent fibrinogen network (D) and whole blood incubation (E). Adapted with permission.[143c] 
Copyright 2018, Elsevier.
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the absence of strong β-sheets). Third, e-gels have strong adhe-
sive properties that are typically absent from other silk fibroin 
hydrogels. Fourth, e-gels have outstanding elastic properties 
and can withstand strains up to 2500%.[149]
The assembly of silk micelles into an e-gel at the electrode 
is completed within minutes. The local drop in pH at the posi-
tive electrode below the isoelectric point of silk screens repul-
sive charges and enables hydrogel formation.[150] Overall, e-gels 
have been proposed to support a range of biomedical applica-
tions (e.g., adhesives for medical devices, sensors, etc.) and 
proof of principle studies are eagerly awaited.
Self-assembling Bombyx mori silk fibroin hydrogels with a 
high β-sheet content have also been explored for a broad range 
of biomedical applications. For example, self-assembling silk 
fibroin hydrogels were loaded with doxorubicin and adminis-
tered locally to breast tumors in mice. Locally administered silk 
fibroin hydrogels loaded with doxorubicin provided a signifi-
cant reduction in primary tumor growth and metastasis when 
compared to equivalent doses of doxorubicin administered sys-
temically.[151] A parallel study that used the same animal model, 
drug, dosing schedule, and treatment strategy showed that the 
heparin-modified polyethylene glycol  (PEG) hydrogels were 
outperformed by the self-assembling silk hydrogel.[152] Self-
assembling silk fibroin hydrogels that use sonication as a trigger 
are ideal for the delivery of biologics. The payload is added fol-
lowing sonication and during the solution-gel transition time 
window. For example, self-assembling silk fibroin hydrogels 
have been examined for the delivery of bevacizumab (a mono-
clonal antibody of antivascular endothelial growth factor) for 
the treatment of age-related macular degeneration.[153]
Direct comparison of a silk fibroin hydrogel formulation with 
the current standard treatment showed that intravitreal injec-
tion in healthy rabbits significantly improved the drug levels 
in the vitreous and aqueous humor when compared to the 
commercial liquid formulation. The bioavailability of the com-
mercial product and the silk fibroin hydrogel formulation was 
similar, but the terminal half-life for the silk hydrogel was two-
fold to threefold higher. This improvement would be expected 
to reduce the number of intravitreal injections required.[153] 
Although the results are encouraging, further optimization of 
the silk fibroin hydrogel is warranted to reduce the initial burst 
release of bevacizumab and the placement of the silk hydrogel, 
because vitreous administration has the potential to obstruct 
the light path into the eye and thereby limit vision.
Self-assembling silk hydrogels are emerging as useful tools 
for the therapeutic delivery of (stem) cells. For example, pan-
creatic islet transplantation is plagued by a functional decline 
and decreased viability of the islets during the peritransplanta-
tion period, so self-assembling silk fibroin hydrogels have been 
examined as a potential delivery system.[154] Silk self-assembly 
was initiated by vortexing, the islet cells were added prior to the 
completion of the solution–gel transition, and the mixture was 
injected into the epididymal fat pad of diabetic mice. Functional 
tests showed that silk fibroin hydrogels loaded with pancreatic 
islets were able to control glucose levels within 4 days, whereas 
this time was extended to 14 days in the absence of the silk car-
rier matrix. Intraperitoneal glucose tolerance tests showed that 
cotransplantation of mesenchymal stem cells (MSCs) with the 
islets improved the function of the graft through the production 
of trophic and angiogenic factors. Furthermore, transplantation 
of minimal islet cell grafts and MSCs (serving as a supporting 
stromal cells) using self-assembling silk fibroin hydrogels 
resulted in euglycemia control in 75% of the transplanted mice 
at day 37, whereas no other treatment combinations success-
fully abolished diabetes.[154] The use of a silk fibroin hydrogel 
maximized the clinical performance; however, histological 
examination showed an unintended complication as the MSCs 
differentiated into osteoblasts at day 42. MSCs are responsive 
to environmental cues (e.g., mechanical forces, cytokines, etc.), 
which indicates that (silk) hydrogels still require fine-tuning to 
ensure the final desired outcome.
9.6. Particles
The preclinical development of silk (nano)particles is often 
aimed at the delivery of cytotoxic small-molecular-weight anti-
cancer drugs (reviewed by ref. [70]). Entrapment into a (nano)
particle changes the pharmacokinetic and biodistribution char-
acteristics of the payload, as these characteristics are now dic-
tated by the carrier and not the physiochemical properties of the 
drug. Therefore, engineering the carriers opens up new possi-
bilities for tuning the overall drug performance; for example, 
by altering the residence time in the blood or the uptake 
mechanism into target cells. Nanoparticles are often proposed 
for solid tumor targeting, as they can exploit the leaky vascula-
ture and reduced lymphatic drainage associated with tumors, 
which results in enhanced permeability and retention (EPR) at 
the target tissue.[155] Inclusion of a targeting ligand can further 
increase the specificity. The EPR effect exploits pathophysi-
ology, but full clinical exploitation remains to be realized.[156] 
Nanoparticles designed for EPR-mediated tumor targeting are 
typically injected into the blood circulation and must therefore 
be compatible with blood. Silk fibroin nanoparticles showed 
very low plasmatic coagulation and the observed response was 
significantly better when compared to silica nanoparticles. 
Furthermore, under simulated venous blood flow, the silk and 
PEGylated silk fibroin nanoparticles also showed low inflam-
mation when compared to silica nanoparticles.[72] Overall, these 
initial studies on the hemocompatibility of silk fibroin nanopar-
ticles are encouraging.
Early studies set out to explore techniques for the manu-
facturing of silk fibroin nanoparticles and to establish their 
respective loading capabilities using (model) drugs (reviewed 
by ref. [157]). Two of the early manufacturing techniques used 
to generate silk fibroin nanoparticles were nanoprecipitation[158] 
and capillary microdot printing.[159] Capillary-dot microprinted 
nanoparticles loaded with curcumin showed extended release 
profiles and a higher in vitro efficiency against breast cancer 
cells when compared to silk/chitosan composite nanoparti-
cles.[159] Nanoparticles generated from Bombyx mori and Anthe-
raea mylitta (the tropical tasar silkworm) silks were stable, 
spherical, negatively charged, and 150–170 nm in diameter, and 
they showed no cytotoxicity at the tested concentrations.[160]
The delivery of small molecular weight drugs with (silk) 
nanoparticles changes their uptake mechanisms (and their 
susceptibility to drug efflux pumps) from passive diffusion 
across the plasma membrane to an energy-dependent endocytic 
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uptake (independent of drug efflux pumps). For these reasons, 
silk fibroin nanoparticles were able to improve anticancer drug 
delivery into drug resistance breast cancer cells.[161]
Once inside the cells, the payloads on silk fibroin nanoparti-
cles can also be activated within lysosomes (i.e., lysosomotropic 
drug delivery) by the low pH and the proteolytic enzymes of lys-
osomes, given the correct intracellular trafficking of the nano-
particles.[162] The lysosomal environment not only triggers drug 
release but is also the site of silk fibroin nanoparticle degrada-
tion.[51] Silk fibroin (nanoparticles) can stabilize a broad spectrum 
of payloads by tailoring the water content, locking the payload into 
place, buffering the microenvironment, and restricting the access 
of degradative enzymes (reviewed in ref. [134]). For example, 
entrapment of L-asparaginase into Bombyx mori silk fibroin nan-
oparticles resulted in an increased resistance to enzymatic deg-
radation, better stability in serum, prolonged storage stability in 
solution, and minimal leakage of the enzyme from the carrier.[163] 
PEGylation of silk fibroin nanoparticles has been exploited to 
improve colloidal stability and to tailor drug release and carrier 
degradation.[164] Magnetically responsive, drug-loaded silk fibroin 
nanoparticles have also been developed by seeding silk with 
Fe3O4 nanoparticles.[165] Subjecting these silk nanoparticles to a 
magnetic field in the tumor area allowed their enrichment in the 
tumor, thereby promoting drug accumulation and an improved 
antitumor response.[165] Silk fibroin nanoparticles have also been 
combined with other silk formats (for example, silk fibroin hydro-
gels) to yield first generation all-silk dual-drug delivery systems.[166]
10. Bioengineered Silks
Recent efforts have focused on developing recombinant forms 
of silks that can be altered at the sequence level to achieve spe-
cific modalities, for example, for biomedical use.[167] Recom-
binant approaches are unique because they allow the design 
and manufacture of bespoke “silks.”[168] For example, key ele-
ments of the spider silk sequence can be lifted and combined 
with polylysine to develop novel biopolymers for the delivery 
of genetic material (reviewed in ref. [169]). Chimeric proteins, 
such as silk-collagen-like proteins[170] or silk-elastin-like pro-
teins (SELPs), are exciting new materials (although the SELPs 
have been extensively studied over the past three decades; 
reviewed in ref. [171]). SELPs are facile biopolymers that can be 
fine-tuned to achieve a desired form and function; for example, 
SELP micelles have been designed for anticancer drug delivery 
that exploits both passive and active tumor targeting. SELPs have 
also been used to generate hydrogels intended for local drug 
release.[171] Many other studies have examined the performance 
of “biopolymer alloys” by blending silk with another biopolymer, 
such as tropoelastin,[172] collagen,[173] and fibronectin[174] or 
have included inorganic ceramics (reviewed in ref. [175]) to 
generate new material systems with expanded function. One of 
the hallmarks of silk is its inherent ability to organize structures 
at the nanometer scale; these structures then assemble, grow, 
and ultimately produce macroscale constructs with defined 
function. The ability of silk to work seamlessly across several 
orders of magnitude is exciting and has motivated the devel-
opment of engineered nanoscale systems. For example, atomic 
force microscopy has been used to drive and direct the 
self-assembly of SELP nanofibers,[176] while macroscopic silk 
constructs have been patterned using ion beam lithography 
to yield diverse silk-like constructs with defined shapes at the 
nanometer scale.[177] Other examples include engineered silk 
oligonucleotide conjugates that direct silk assembly into a par-
allel, antiparallel, and branched configurations (reviewed in 
ref. [178]). The timely review by Aigner et al. provides extensive 
insight into this important branch of silk research.[167a] Here, 
we only provide a selection of a few examples of recombinant 
silks (Table 4), with a specific reference to silk (nano)particles.
Recombinant silk proteins have been inspired by Araneus 
diadematus fibroin 4 (ADF4); ADF4 is from the common Euro-
pean garden spider. ADF4 is one of the most widely studied 
spidroins[5a] and has been used to prepare microcapsules for 
drug delivery by exploiting its self-assembly at an emulsion 
interface.[187] The resulting spider silk-based carriers are useful 
for encapsulating low molecular weight drugs under mild con-
ditions, which maintains the activity of the payload.[187] Expo-
sure of ADF4-like silks to potassium chloride (>400 × 10−6 M) 
generates particles,[188] which have been extensively character-
ized for their ability to entrap and release (small molecular 
weight) payloads.[189] Silk sequence modifications are now 
yielding cationic proteins that can be loaded with low and high 
molecular anionic payloads (e.g., nucleic acids).[190] Libraries of 
silk proteins containing modifications, such as the RGD inte-
grin binding domain and the Tat cell penetrating peptide, have 
been designed to enhance cellular uptake and drug delivery.[191] 
The first inroads have been made to unravel the mechanisms 
for endocytic (e.g., caveolae, clathrin-mediated) uptake of nano-
particles into cells using putative chemical inhibitors.[192]
Recombinant technologies have also been exploited to gen-
erate silks inspired by major ampullate spidroin 1 (MaSp1) 
from the Gold Orb-web spider (Nephila clavipes). For example, 
MaSp1-like proteins have been modified with poly(L-lysine) 
cationic sequences to allow complexation with nucleic acids via 
electrostatic interactions for use in gene delivery. These engi-
neered protein vectors demonstrated excellent DNase resistance 
and gave transfection efficiencies similar to those achieved with 
the commercial reagent Lipofectamine 2000. The silk sequence 
has also been fused with tumor-homing peptides (e.g., F3, 
Lyp1 CGKRK) and attachment ligands (e.g., RGD to exploit cell 
binding and receptor-mediated endocytosis) to enhance their 
targeting capabilities.[61c,93,166] These recombinant silks formed 
nanometer-sized globular complexes with plasmid DNA (150–
250 nm in diameter), and they demonstrated significantly 
improved target specificity for melanoma and highly metastatic 
human breast cancer cells.[93,166] A silk vector harboring the 
tumor-homing peptide F3 showed minimal toxicity in healthy 
cells, the best tumor specificity, and a capability to deliver its 
payload in a human orthotopic breast cancer model.[193] Overall, 
these studies demonstrate the potential of silk-based delivery 
systems as nonviral gene delivery vectors.
11. (Old) New Silk Industries: Opportunities  
and Challenges for the Road Ahead
Current production routes for Bombyx mori silk are well estab-
lished and are the foundation of several products in routine 
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clinical use today. Following a period of decline, global silk pro-
duction is growing once again and has the capacity to keep up 
with a growing silk demand for (bio)medical use.[19] However, 
sericulture is an agricultural process that depends on several fac-
tors, including, but not limited to, climate, seasonal variations, 
disease and pest control, and the susceptibility of silkworms to 
common pesticides used in other agriculture sectors (within 
geographical proximity, with fatal consequences for the silk-
worm). The silk community should make a concentrated effort 
to work with well-controlled silk cocoon stocks with a known 
process history in order to propel the silk research community 
into working practices that align with Good Laboratory Practice. 
This type of approach would be invaluable for improving com-
parisons across different studies and accelerating clinical trans-
lation. While public guidelines exist for CE-marked organic 
sericulture, the production of Bombyx mori silk for medical use 
is shrouded in secrecy and proprietary protocols. For example, 
the domesticated Bombyx mori silkworm line used for silk 
sutures and surgical meshes is a well-kept secret.
The optimal environmental condition during cocoon spin-
ning is another unknown. Laboratory experiments indicate that 
silk cocoons spun in a low humidity environment do not require 
degumming by boiling in an aqueous alkaline solution; instead, 
physical manipulation is sufficient for quantitative removal of 
sericin.[194] Of course, adequate silk cleaning is critical for pro-
ducing hypoallergenic silk. Eliminating the boiling step also 
preserves the silk structure, thereby yielding a monodispersed 
biopolymer (rather than polydispersed silk fibroin fragments). 
This, in turn, is likely to simplify the regulatory requirements 
that currently mandate a well-defined material stock (although 
these regulations vary depending on the specific classification 
of the final product as “medical device,” “excipient,” “advanced 
therapy medicinal product,” “novel chemical entity,” etc.).
Full reverse engineering of the silk cocoon is complex from 
both industrial and regulatory perspectives. At present, all 
licensed (Bombyx mori) silk products in the USA and EU are 
considered medical devices based on the nascent, but deg-
ummed, silk fiber (Tables 1, and 2). By contrast, reverse engi-
neered silk is marketed as cosmetics to navigate regulatory 
challenges. Irrespective of the medical or cosmetic use, the cur-
rent silk production technologies are batch processes, which go 
against the current industrial efforts aimed at continuous manu-
facturing to ultimately improve product reliability and cut costs.
Manipulating (the germ line of) silkworms by genetic engi-
neering opens up new possibilities to generate improved silks, 
for example, by inserting spider silk sequences into Bombyx 
mori silk to improve the mechanical properties of the in vivo 
spun fiber.[195] Another possibility is to exploit the silkworm as 
a biosynthetic host to synthesize xenogenic proteins or func-
tional silks (e.g., insertion of green fluorescent protein, RGD 
sequences, etc.[196]). Improvements in genome editing are 
likely to increase the protein yields, ultimately leading to new 
silkworm lines (e.g., that produce modified silk sequences, etc.) 
of appreciable economic value.
Recombinant proteins are routinely used in the clinic and are 
manufactured on a large scale by the pharmaceutical industry. 
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Table 4. Examples of silk and functional motifs used for engineered silk biomaterials.
Motif Amino acid sequence Function Reference
Major ampullate spidroin 1 (MaSp1) 
from Nephila clavipes
GRGGLGGQGAGAAAAAGGAGQGGYGGLGSQG Repeated domain [179]
GAGAAAAAGGAG Hydrophobic block [180]
QGGYGGLGSQGSGRGGLGGQ Hydrophilic block [180]
ADF-4 from the garden spider 
Araneus diadematus
GSSAAAAAAAASGPGGYGPENQGPSGPGGYGPGGP Repeated domain [181]
B. mori silkworm heavy chain GAGAGS Beta-sheet motif [182]
[GERGDLGPQGIAGQRGVV(GER)3GAS]8GPPGPCCGGG [TGRGDSPAS]8 Repeated domain [183]




Controlled hydroxyapatite growth [39a]
R5 unit of silaffin-1 precursor 
polypeptide from Clavulinopsis fusiformis
SSKKSGSYSGSKGSKRRIL Induce silica precipitation [184]
Bone sialoprotein MKTALILLSI LGMACAFSMK NLHRRVKIED SEENGVFKYR PRYY-
LYKHAY FYPHLKRFPV QGSSDSSEEN GDDSSEEEEE EEETSNEGEN 
NEESNEDEDS EAENTTLSAT TLGYGEDATP GTGYTGLAAI QLPKKAGDIT 
NKATKEKESD EEEEEEEEGN ENEESEAEVD ENEQGINGTS TNSTE-
AENGN GSSGGDNGEE GEEESVTGAN AEDTTETGRQ GKGTSKTTTS 
PNGGFEPTTP PQVYRTTSPP FGKTTTVEYE GEYEYTGANE YDNGYEIYES 
ENGEPRGDNY RAYEDEYSYF KGQGYDGYDG QNYYHHQ
Induce bone regeneration [93]
Cell penetrating peptide ppTG1 GLFKALLKLLKSLWKLLLKA Delivery system into cells [61c,185]
Tumor homing peptide F3 KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK Target specificity to tumor cells [93,186]
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Therefore, the necessary expertise exists within the health-
care sector to manufacture these complex products to clinical 
specifications. Already, today, recombinant DNA technology, 
in combination with Escherichia coli expression systems, has 
revolutionized silk research[167a] and is opening up new com-
mercial avenues (Table 5). However, silk presents a number of 
specific challenges; for example, the silk molecules cannot be 
post-translationally modified, but this is required to faithfully 
mimic the silk protein.[197] The expression of native-sized silk 
proteins is also not possible using standard E. coli expression 
systems because of the highly repetitive nature of the gene 
constructs, the very high glycine content of the protein, and 
the high molecular weight of the product (250–320 kDa). These 
challenges can be addressed by using genetically modified 
E. coli with an elevated glycyl-tRNA pool, which give native-like 
silk proteins, albeit with a low protein yield.[198] Another com-
plication is that silk inspired proteins with repeated domains 
containing Ala-rich sequences are poorly soluble in water and 
buffers. Inclusion of a cationic histidine tag with the hydro-
phobic crystallizable silk sequences improves the aqueous 
solubility of the resulting protein.[61c] The economic issues 
and greenhouse gas emissions associated with E. coli cultures 
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Table 5. Examples of current companies with R&D and/or silk-based products for biomedical applications.
Company Location Silk Products Clinical trial(s)








Vaxess Inc. Boston, MA, USA Bombyx mori Encapsulating and stabilizing payloadsc)
Silk Therapeutics Inc. Medford, MA, USA Bombyx mori Anti-aging skin carea)
Cocoon Biotech Inc. Cambridge, MA, USA Bombyx mori Silk-based drug deliveryc) (e.g., hydrogels, micro-
spheres for ophthalmic and osteoarthritis)
Silk Technologies Ltd. Plymouth, MN, USA Bombyx mori Topical occular therapy (e.g., dry eye); silk-derived 
protein pharmacological active ingredientc)
Oxford Biomaterials Ltd. Oxford, UK Bombyx mori and others Vascular graftsc)




Neurotex Ltd. Oxford, UK ND Spidrex nerve conduitc)
AL.PRE.TEC. S.r.l. San Donà di Piave, Italy Bombyx mori Textiles for skin diseases (e.g. dermatitis)a) andc), 
DermaSilk (see Table2)a)
Suzhou Soho Biomaterial Science 
and Technology Co., Ltd, China
Suzhou, Jiangsu Prov-
ince, China
Bombyx mori Sidaiyi wound dressinga) biomedical use of other silk 
formatsc)
NCT01993030
Zhejiang Xingyue Biotechnology 
Co., Ltd.
Hangzhou, China Bombyx mori HQ Matrix medical wound dressingb); HQ Matrix 
Soft Tissue Mesh (hernia repair)b)
NCT01993030
NCT02487628
Daewoong-Bio Inc. Seoul, South Korea Bombyx mori Tympasil silk patcha) (tympanic membrane 
perforation)
Yes, but not registered at 
ClinicalTrials.gov




Coating of breast implantsb)
Yes, but not registered at 
ClinicalTrials.gov
Spiber Technologies AB Stockholm, Sweden Recombinant spider silk Spiber genetically modified for new biomedical 
functionsc)
SolvNT protein solubility tagc)
Spiber Inc. Yamagata, Japan Recombinant spider silk QMONOS silk fibers, apparel and automotivec), 
biomedical secondary
Bolt Threads Inc. Emeryville, CA, USA Recombinant spider silk Silk fiber and Bolt Microsilk clothing (c) and lim-
iteda)). Biomedical use undisclosed
The Synthetic Bioproducts Center Logan, UT, USA Recombinant spider silk Proprietary recombinant silks for biomedical 
applicationsc)
Kraig Biocraft Laboratories Inc. Ann Arbor, MI, USA Bombyx mori Silk modified with  spider silk sequences & produced 
in  silkworms. Dragon Silk and Monster 
Silk lead products as 
ballistic shoot packs.c) Biomedical use
undisclosed
a)Commercial product/marketed; b)In clinical trials; c)In development.
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are other critical aspects that must be considered for the 
development of a sustainable recombinant silk industry.[199]
11.1. Staying on the “Silk Road”
Perhaps one of the most important aspects to consider 
regarding the future of the biomedical use of silk is the 
safeguarding of the silk development pipeline. Silk is a truly 
amazing biopolymer that has inspired generations of scientists 
and is likely to continue to do so. However, researchers must 
not get carried away or overpromise. In a globally connected 
world, with many clinically unmet needs, the news of promising 
biomedical research has the potential to make headlines simply 
by the fact that the material is “silk.” We must not exploit the 
familiarity of the general population with common silk for the 
purpose of short term gains. The road to the clinical translation 
of basic biomedical research is a long and tortuous one—this 
also applies to silk research. The path is difficult and requires 
a carefully measured balance of optimism (to inspire people) 
and realism (to avoid a silk bubble). It is important to learn 
from past failures as well as from the challenges experienced 
in allied fields.[200] Clearly, silk has its limitations, as detailed 
in this review; for example, i) it is an expensive biopolymer 
when compared to mass-produced fully synthetic polymers, ii) 
sericulture is a labor-intensive agricultural process and highly 
responsive to its environment, which ultimately impacts silk 
quality, and iii) the durability of recombinant spider silks might 
be challenging based on the simple premise that the material 
has evolved in nature as a short-term high-performance mate-
rial (e.g., orb-weaver spiders repair or build a new web often 
daily). It is therefore important to consider alternative materials 
as well that are able to perform, and perhaps surpass, the func-
tion of silk. The emergence of fully synthetic sutures is a testa-
ment to this type of development. However, silk fibroin sutures 
still remain the first choice for specialized surgeries, indicating 
that silk should serve as a blueprint for next generation sutures.
11.2. The Current Silk Drivers
Silk continues to inspire and serves as the thread for exploration 
new avenues: curiosity-driven research and learning from nature 
are key elements for innovation. Newly emerging silk industries 
are now translating research findings that go beyond fiber tech-
nology[201] (Table 5). As these technologies, which often have their 
origins in the academic setting, move from the public domain into 
the industrial space, tracking their progress becomes more dif-
ficult. However, the first products have entered clinical trials and 
products are emerging on the market (Table 5 and detailed below).
Recombinant (spider) silks are the lifelines of many small to 
medium sized enterprises. Spider silk is a prime focus, because 
this remarkable biopolymer cannot be obtained at an industrial 
scale by “farming.” Instead, genetic engineering and recom-
binant expression systems are essential, and they also provide 
greater flexibility and rapid production of novel silk-inspired pro-
teins. The (pharmaceutical) industry is accustomed to working 
with recombinant proteins, and these provide many opportuni-
ties for patterning and proprietary knowledge. Many companies 
currently working with recombinant silks are generating fibers. 
The remarkable mechanical properties of spider silk, coupled 
with its processing under ambient conditions in an all aqueous 
environment, might serve as an inspiration for this new industry.
The Synthetic Bioproducts Center, under the leadership of 
Randy Lewis (Utah State University, Logan, UT, USA), produces 
synthetic spider silks for biomedical engineering applications 
using a range of expression hosts, including genetically modified 
goats. These genetically engineered dairy goats carry the dragline 
silk genes of the Nephila clavipes (identified by the Lewis lab[202]) 
in mammary gland cells and excrete soluble silk in their milk. 
This silk can be extracted and subsequently spun into fibers. The 
genetically modified goats were developed by Nexia Biotechnolo-
gies Inc. (Quebec, Canada) in the early 2000s and subsequently 
acquired by Randy Lewis. Nexia Biotechnologies and the Materials 
Science Team of the U.S. Army and Soldier Biological Chemical 
Command (Natick, MA, USA) expressed the silk proteins ADF-3/
MaSp2 and MaSp1 for the first time in mammalian cells,[203] 
thereby laying the foundation for subsequent work in goats.
AMSilk GmbH (Planegg/Munich, Germany) is a spin-out 
company based on seminal work by Scheibel and co-workers and 
is the world’s first industrial supplier of recombinant silk biopoly-
mers across a range of applications. AMSilk exploits ADF4-
inspired silks (and others) to generate high quality materials for 
apparel, cosmetic, industrial, and structural applications. Biosteel 
fiber is their leading product, and it is at various developmental 
stages for application in the footwear and automotive industries. 
AMSilk received ISO 13 485 accreditation in 2017—a prerequi-
site for initiating clinical studies in humans. In February 2018, 
AMSilk announced the launch of the POSIS Phase I clinical trial, 
in partnership with POLYTECH Health & Aesthetics GmbH. 
The trial examines the performance of silicone breast implants 
coated with ADF4-based silk (BioShield-S1) (SILKline) in several 
human subjects at a number of University hospitals in Austria 
(with the option to expand to other centers). This trial has been 
underpinned by both proprietary product development efforts 
as well as animal studies available in the public domain. For 
example, ADF4 coated silicone implants showed no acute toxicity 
or immunogenicity and they reduced postoperative inflamma-
tion and minimized implant-induced capsule thickness and con-
traction when compared to uncoated control implants.[204]
Founded in 2008, Spiber Technologies AB (Stockholm, 
Sweden) produces silk biomaterials, which can be processed 
into a range of material formats (e.g., fibers, films, foams, coat-
ings, etc.). Their work is underpinned by academia–industry 
collaborations that support the preclinical research and devel-
opment pipeline exploiting spider silk for biomedical applica-
tions (e.g., cell–matrix interactions, culture matrices, surface 
modifications, electrochemical meshes, etc.).[205] Scientists 
affiliated with Spiber Technologies AB have also unraveled the 
molecular mechanisms of spider silk spinning[206] in order to 
develop better biomimetic fibers.[207]
The pH-sensitive N-terminal of silk enables the silk protein 
to stay in solution at very high protein concentrations; thus, 
recombinant fusion of the N-terminal domain converted an 
aggregation-prone therapeutic protein to its hypersoluble coun-
terpart (this technology is now marketed as SolvNT).[208] This 
strategy also simplified protein purification, improved yields, 
and allowed the expression of nontransmembrane proteins that 
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are otherwise refractory to recombinant production. SolvNT 
exemplifies how silk continues to amaze us, and goes beyond 
applications we are accustomed to.
Spiber Inc. (Yamagata, Japan), founded by Kazuhide Seki-
yama in 2007 as a start-up at Keio University, produces var-
ious types of recombinant proteins, especially spider silk-like 
proteins (note that Spiber Inc. is an independent company 
from Spiber Technologies AB). The synthetic spider thread 
QMONOS (based on the Japanese word kumonosu for spider 
web) is a technology fiber that has been fed into several proof 
of concept items, such as a child’s dress, and the North Face 
branded MOON PARKA. The current target markets are the 
apparel and automotive segments, with healthcare materials 
serving as an emerging future area.
Another contender in the recombinant silk market space is Bolt 
Threads Inc. (Emeryville, CA, USA), which produces silk fibers by 
wet spinning (Engineered Silk) using advanced yeast expression 
systems. The recombinant silk is produced on a scale that makes 
it a viable contender for broad applications. To date, Bolt Threads 
has already introduced several engineered Silk fiber and Bolt 
Microsilk products (e.g., ties, clothing, etc). Whether these mate-
rials will also enter the healthcare arena is not known at present.
12. Conclusions
In this progress report, we have unraveled some of the mys-
teries of silk and critically examined the current and emerging 
clinical uses of silk. We eagerly await further clinical reports, 
especially on engineered second-generation silk materials, such 
as “silk”-coated implants. For the past 5000 years, silk has capti-
vated humans, and it continues to amaze us as we explore new 
applications. The silk biopolymer represents a pioneer material 
for medical applications today, and yet, even after many centu-
ries, it continues to be a valued suture material. As we continue 
to extract secrets from silk, we will be able to develop new “old 
materials” to address current and future biomedical needs.
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